Alliance HealthCare Services (AIQ) 10-Q 8 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 06, 2014
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Entity Registrant Name	'Alliance HealthCare Services, Inc	'
Entity Central Index Key	'0000817135	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	10,729,353

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$31,317	$34,702
Accounts receivable, net of allowance for doubtful accounts	64,133	63,713
Deferred income taxes	21,849	21,849
Prepaid expenses	6,625	7,553
Other receivables	2,734	2,796
Total current assets	126,658	130,613
Equipment, at cost	825,089	824,103
Less accumulated depreciation	-671,964	-654,350
Equipment, net	153,125	169,753
Goodwill	56,975	56,975
Other intangible assets, net	98,158	101,801
Deferred financing costs, net	9,047	9,873
Other assets	24,122	20,832
Total assets	468,085	489,847
Current liabilities:	'	'
Accounts payable	9,399	11,990
Accrued compensation and related expenses	17,693	21,166
Accrued interest payable	3,110	1,645
Other accrued liabilities	23,463	22,002
Current portion of long-term debt	13,292	15,066
Total current liabilities	66,957	71,869
Long-term debt, net of current portion	494,704	514,608
Other liabilities	4,826	4,714
Deferred income taxes	32,618	35,273
Total liabilities	599,105	626,464
Commitments and contingencies	'	'
Stockholders’ deficit:	'	'
Common stock	525	524
Treasury stock	-3,138	-2,998
Additional paid-in capital	26,588	23,521
Accumulated comprehensive loss	-297	-82
Accumulated deficit	-199,994	-204,709
Total stockholders’ deficit attributable to Alliance HealthCare Services, Inc.	-176,316	-183,744
Noncontrolling interest	45,296	47,127
Total stockholders’ deficit	-131,020	-136,617
Total liabilities and stockholders’ deficit	$468,085	$489,847

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenues	$111,238	$114,418	$216,603	$224,800
Costs and expenses:	'	'	'	'
Cost of revenues, excluding depreciation and amortization	59,627	60,094	116,567	120,733
Selling, general and administrative expenses	19,384	20,247	38,123	39,342
Transaction costs	937	0	939	80
Severance and related costs	1,727	298	1,860	646
Impairment charges	236	4,867	236	4,867
Loss on extinguishment of debt	0	17,069	0	17,069
Depreciation expense	14,274	16,322	30,069	32,838
Amortization expense	1,957	2,911	3,909	6,705
Interest expense and other, net	6,124	11,053	12,362	23,325
Other income, net	-408	-385	-331	-1,287
Total costs and expenses	103,858	132,476	203,734	244,318
(Loss) income before income taxes, earnings from unconsolidated investees, and noncontrolling interest	7,380	-18,058	12,869	-19,518
Income tax (benefit) expense	1,802	-7,195	3,309	-7,333
Earnings from unconsolidated investees	-1,242	-1,408	-2,240	-3,142
Net (loss) income	6,820	-9,455	11,800	-9,043
Less: Net income attributable to noncontrolling interest	-4,036	-3,509	-7,085	-6,339
Net (loss) income attributable to Alliance HealthCare Services, Inc.	2,784	-12,964	4,715	-15,382
Comprehensive (loss) income, net of taxes:	'	'	'	'
Net (loss) income attributable to Alliance HealthCare Services, Inc.	2,784	-12,964	4,715	-15,382
Unrealized loss on hedging transactions, net of taxes	-235	-192	-215	-272
Comprehensive (loss) income, net of taxes	$2,549	($13,156)	$4,500	($15,654)
(Loss) income per common share attributable to Alliance HealthCare Services, Inc.:	'	'	'	'
Basic (dollars per share)	$0.26	($1.22)	$0.44	($1.45)
Diluted (dollars per share)	$0.26	($1.22)	$0.43	($1.45)
Weighted-average number of shares of common stock and common stock equivalents:	'	'	'	'
Basic (shares)	10,671	10,629	10,669	10,629
Diluted (shares)	10,854	10,629	10,872	10,629

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Operating activities:	'	'
Net (loss) income	$11,800	($9,043)
Adjustments to reconcile net (loss) income to net cash provided by operating activities:	'	'
Provision for doubtful accounts	1,146	1,577
Share-based payment	710	735
Depreciation and amortization	33,978	39,543
Amortization of deferred financing costs	948	2,051
Accretion of discount on long-term debt	222	754
Adjustment of derivatives to fair value	355	340
Distributions (less) more than undistributed earnings from investees	224	-19
Deferred income taxes	-2,655	-7,341
Gain on sale of assets	-185	-1,109
Loss on extinguishment of debt	0	-17,069
Impairment charges	236	4,867
Excess tax benefit from share-based payment arrangements	-515	0
Changes in operating assets and liabilities, net of the effects of acquisitions:	'	'
Accounts receivable	-1,566	-3,067
Prepaid expenses	1,109	-2,378
Other receivables	62	-337
Other assets	-26	172
Accounts payable	-2,485	-1,885
Accrued compensation and related expenses	-3,473	-3,512
Accrued interest payable	1,465	-2,574
Income taxes payable	6	0
Other accrued liabilities	1,488	-3,330
Net cash provided by operating activities	42,844	32,513
Investing activities:	'	'
Equipment purchases	-13,256	-10,357
Decrease (increase) in deposits on equipment	-3,628	3,884
Acquisitions, net of cash received	-1,529	0
Proceeds from sale of assets	570	2,258
Net cash used in investing activities	-17,843	-4,215
Financing activities:	'	'
Principal payments on equipment debt	-5,450	-7,269
Proceeds from equipment debt	0	4,845
Proceeds from term loan facility	0	337,900
Principal payments on term loan facility	-2,450	-340,435
Principal payments on revolving loan facility	-32,000	0
Proceeds from revolving loan facility	18,000	0
Payments of debt issuance costs	0	-9,494
Noncontrolling interest in subsidiaries	-6,573	-6,848
Equity purchase of noncontrolling interest	-691	0
Excess tax benefit from share-based payment arrangements	515	0
Proceeds from shared-based payment arrangements	403	29
Purchase of treasury stock	-140	0
Net cash used in financing activities	-28,386	-21,272
Net increase (decrease) in cash and cash equivalents	-3,385	7,026
Cash and cash equivalents, beginning of period	34,702	39,977
Cash and cash equivalents, end of period	31,317	47,003
Supplemental disclosure of cash flow information:	'	'
Interest paid	9,877	23,528
Income taxes paid, net of refunds	4,991	1,927
Supplemental disclosure of non-cash investing and financing activities:	'	'
Comprehensive loss from hedging transactions, net of taxes	215	272
Equipment purchases in accounts payable	666	634
Adjustment to equity of noncontrolling interest	$1,700	$0

Basis_of_Presentation_Principl

Basis of Presentation, Principles of Consolidation, and Use of Estimates	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation, Principles of Consolidation, and Use of Estimates	'
	Basis of Presentation, Principles of Consolidation, and Use of Estimates
	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared by Alliance HealthCare Services, Inc. (the “Company”) in accordance with accounting principles generally accepted in the United States of America and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles (“GAAP”) for complete financial statements. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the quarter and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements for the year ended December 31, 2013.
	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company include the assets, liabilities, revenues and expenses of all majority-owned subsidiaries over which the Company exercises control. Intercompany transactions have been eliminated. The Company records noncontrolling interest related to its consolidated subsidiaries which are not wholly owned. Investments in non-consolidated investees are accounted for under the equity method.
	Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Transactions

Transactions	6 Months Ended
	Jun. 30, 2014
Transactions [Abstract]	'
Transactions	'
	Transactions
	Restructuring Plan
	On August 4, 2011, the Company’s board of directors approved a restructuring plan that included a significant organizational restructure and a cost savings and efficiency initiative. The Company initiated this restructuring plan in the third quarter of 2011. During the six months ended June 30, 2014 and , the Company recorded $2,455 related to restructuring charges, of which the Company recorded $1,640 in Selling, general and administrative expenses, and $815 in Cost of revenues, excluding depreciation and amortization. The Company also recorded $1,860 in Severance and related costs, primarily as a result of the departure of one of its executive officers during the second quarter of 2014. During the six months ended June 30, 2013, the Company recorded $3,363 related to restructuring charges, of which the Company recorded $2,608 in Selling, general and administrative expenses; $646 in Severance and related costs; and $109 in Cost of revenues, excluding depreciation and amortization.

ShareBased_Payment

Share-Based Payment	6 Months Ended
	Jun. 30, 2014
Share-based Compensation [Abstract]	'
Share-Based Payment	'
	Share-Based Payment
	The Company has adopted ASC 718, “Compensation—Stock Compensation,” and has elected to follow the alternative transition method as described in ASC 718 for computing its beginning additional paid-in capital pool. In addition, the Company treats the tax deductions from stock options as being realized when they reduce taxes payable in accordance with the principles and timing under the relevant tax law.
	Stock Option Plans and Awards
	In November 1999, the Company adopted an employee stock option plan (as amended and restated, the “1999 Equity Plan”) pursuant to which options and awards with respect to a total of 2,205,000 shares have become available for grant. As of June 30, 2014, a total of 550,605 shares remained available for grant under the 1999 Equity Plan. Options are granted with exercise prices equal to the fair value of the Company’s common stock at the date of grant. All options have 10-year terms. Options granted after January 1, 2008 are typically time based and vest in equal traunches over three or four years. During the year ended December 31, 2013, there were no options in which vesting was accelerated. During the six months ended June 30, 2014, there were no options in which vesting was accelerated. Prior to January 1, 2008, subsequent stock options granted under the 1999 Equity Plan to employees were always time options which vest 5% in the first year, 20% in the second year and 25% in years three through five.
	The Company uses the Black-Scholes option pricing model to value the compensation expense associated with share-based payment awards. The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the assumptions noted in the table below. In addition, forfeitures are estimated when recognizing compensation expense and the estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.
	The following weighted average assumptions were used in the estimated grant date fair value calculations for stock option awards:
		Six Months Ended June 30,
		2013		2014
	Risk free interest rate	1.06	%	1.83	%
	Expected dividend yield	—	%	—	%
	Expected stock price volatility	65.7	%	66.3	%
	Average expected life (in years)	5.99		6
	Through March 31, 2012, the expected stock price volatility rates are based on the historical volatility of the Company’s common stock and peer implied volatility. The average expected life, representing the weighted-average period of time that options or awards granted are expected to be outstanding, is calculated using the simplified method described in ASC 718, as the Company did not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected terms and experienced a change in the types of employees that receive share grants. Beginning with the second quarter of 2012, the Company changed its calculation methodology for its stock price volatility and average expected life, which are now based on its own historical data. The risk free interest rates have been, and continue to be, based on the United States Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option or award.
	The following table summarizes the Company’s stock option activity:
		Number of		Weighted-		Weighted-	Aggregate
		Shares		Average		Average	Intrinsic
				Exercise Price		Remaining	Value
						Contractual
						Term
	Outstanding at December 31, 2013	803,617		$	20.83
	Granted	45,783		28.97
	Exercised	(67,657	)	6.32
	Canceled	(129,489	)	11.33
	Outstanding at June 30, 2014	652,254		$	21.64	6.26	$	6,124
	Vested and expected to vest in the future at June 30, 2014	638,467		$	21.6	6.28	$	6,053
	Exercisable at June 30, 2014	432,247		$	21.88	5.51	$	4,560
	The weighted average grant date fair value of options granted during the six months ended June 30, 2013 and 2014 was $7.42 per share and $17.56 per share, respectively. Total stock options exercised was 67,657 during the six months ended June 30, 2014. There were 3,665 options exercised during the six months ended June 30, 2013.
	The following table summarizes the Company’s unvested stock option activity:
		Shares		Weighted-Average
				Grant-Date
				Fair Value
	Unvested at December 31, 2013	376,024		$	8.1
	Granted	45,783		17.56
	Vested	(83,654	)	5.61
	Canceled	(113,888	)	4.76
	Unvested at June 30, 2014	224,265		$	12.58
	At June 30, 2014, the total unrecognized fair value share-based payment related to unvested stock options granted to employees was $2,074, which is expected to be recognized over a remaining weighted-average period of 2.50 years. The valuation model applied in this calculation utilizes highly subjective assumptions that could potentially change over time, including the expected forfeiture rate and performance targets. Therefore, the amount of unrecognized share-based payment noted above does not necessarily represent the value that will ultimately be realized by the Company in the consolidated statements of operations and comprehensive income (loss). The total fair value of shares vested during the six months ended June 30, 2013 and 2014 was $1,029 and $469, respectively.
	Restricted Stock Awards
	The 1999 Equity Plan, as amended and restated, permits the award of restricted stock, restricted stock units, stock bonus awards and performance-based awards. During 2012, awards to certain employees either cliff vested after one year, or vest annually in 33.3% increments over three years. During 2013, awards to certain employees vested immediately upon the date of grant, or cliff vest after one year provided that the employee remains continuously employed through the issuance date. The Company grants restricted stock awards to non-employee directors of the Company who are unaffiliated with Oaktree Capital Management, LLC (“Oaktree”) and MTS Health Investors, LLC (“MTS”) (“unaffiliated directors”). These awards to unaffiliated directors cliff vest after one year based on the unaffiliated directors’ continued service with the Company through that date.
	For the six months ended June 30, 2013 and 2014, the Company recorded share-based payment related to restricted stock awards of $251 and $245, respectively. The weighted-average grant-date fair value of restricted stock awards granted during the six months ended June 30, 2013 was $6.38 per share. Twenty-five thousand restricted stock units ("RSU") were granted to executive management in the second quarter of 2014, which vest based upon achieving certain market performance conditions. Specifically, the Company's closing stock price per common share must equal or exceed a value of $40.00 per share for 10 consecutive days between the dates of January 1, 2015 and April 21, 2017. If these conditions are not achieved before April 21, 2017, these RSUs will expire. In accordance with ASC 718, expense related to restricted stock units that vest based on achieving a market condition should not be recognized until the derived vesting period has been met, and at such time the derived vesting period becomes the requisite service period. Since the market condition is only able to be achieved on or after January 1, 2015, the derived service period has not yet began as of June 30, 2014. Based on this guidance, the Company has not recognized any expense related to these RSUs during the six months ended June 30, 2014.
	The following table summarizes the Company’s restricted stock activity:
		Shares		Weighted-Average
				Grant-Date
				Fair Value
	Unvested at January 1, 2012	273,308
	Granted to employees	38,075
	Granted to non-employee directors	19,469
	Vested	(119,968	)
	Canceled	(106,340	)
	Unvested at December 31, 2012	104,544
	Granted to employees	14,100
	Granted to non-employee directors	13,619
	Vested	(54,038	)
	Canceled	(7,334	)
	Unvested at December 31, 2013	70,891		$	7.01
	Granted to employees	25,000		30.33
	Granted to non-employee directors	—		—
	Vested	(31,000	)	30.33
	Canceled	(26,272	)	6.36
	Unvested at June 30, 2014	38,619		$	28.36
	At June 30, 2014, the total unrecognized fair value share-based payment related to restricted stock awards granted to employees was $735, which is expected to be recognized over a remaining weighted-average period of 2.81 years. At June 30, 2014, the total unrecognized fair value share-based payment related to the restricted stock awards granted to unaffiliated directors was $349, which is expected to be recognized over a remaining weighted-average period of 0.50 years.
	Directors' Compensation Program
	In 2012 and 2013, under the compensation program for non-employee directors in effect during 2012, non-employee directors earned an annual fee of $40 for their services as directors. In addition, each Unaffiliated Director, received a restricted stock unit award on December 31 for the number of shares of our Common Stock having a value equal to $40, using the average share price of our Common Stock over the 15-day period preceding the grant date. These restricted stock unit awards vest on the first anniversary of their respective date of grant contingent upon the Unaffiliated Director's continued service to the Company through that date. In addition, each Unaffiliated Director receives additional annual cash compensation of $40, paid in equal quarterly installments, for serving on the Board during 2012 and 2013. Beginning October 1, 2013, the Chairman of the Board, Mr. Buckelew, is entitled to restricted stock units having a value equal to $138 as compensation for a service period of one year, for the 24 month period following his resignation as the Company's CEO. The number of units Mr. Buckelew receives, having a value equal to $138, divided by the closing share price of the Company’s stock on December 31, rounded down to the nearest whole share. On December 31, 2012 and 2013, each Oaktree/MTS Director received additional cash compensation of $80, for serving on the Board during 2012 and 2013, respectively. Also during 2012 and 2013, non-employee directors who served as members of our Audit Committee received an additional $15, and the non-employee director who served as Chairman of our Audit Committee received an additional $30. In 2012 and 2013, non-employee directors who served as members of our Nominating Committee, Compensation Committee and Strategy & Finance Committee received an additional $5, and the non-employee director who served as Chairman of our Strategy and Finance Committee received an additional $25. In 2012 and 2013, non-employee directors were reimbursed for travel expenses related to their Board service.
In 2014, under the revised compensation program for non-employee directors in effect during 2014, non-employee directors earn an annual fee of $40 for their services as directors. In addition, each Unaffiliated Director, will receive a restricted stock unit award on December 31 for the number of shares of our Common Stock having a value equal to $140, using the average share price of our Common Stock over the 15-day period preceding the grant date. These restricted stock unit awards vest on the first anniversary of their respective date of grant contingent upon the Unaffiliated Director's continued service to the Company through that date. In addition to the annual $40 fee for all non-employee directors, each Affiliated Director receives additional annual cash compensation of $140, paid in one annual installment, for serving on the Board during 2014. The Chairman of the Board and other committee chairs' and members' compensation program remains unaltered from the above discussion.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	Income Taxes In July 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") number 2013-11, "Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists - a consensus of the FASB Emerging Issues Task Force". ASU 2013-11 generally requires, with some exceptions, an entity to present its unrecognized tax benefits as it relates to its net operating loss carryforwards, similar tax losses, or tax credit carryforwards, as a reduction of deferred tax assets when settlement in this regard is available under the tax law of the applicable taxing jurisdiction as of the balance sheet reporting date. It is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. Retrospective application is permitted. The adoption of ASU 2013-11 did not affect the Company's results of operations, cash flows, or financial position.
	Derivatives and Hedging In July 2013, the FASB issued ASU number 2013-10, “Derivatives and Hedging (Topic 815) — Inclusion of the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a Benchmark Interest Rate for Hedge Accounting Purposes.” ASU 2013-10 permits the use of the Fed Funds Effective Swap Rate as a U.S. benchmark interest rate for hedge accounting purposes. The ASU also removes the restriction on using different benchmark rates for similar hedges. ASU No. 2013-10 is effective for qualifying new or redesignated hedging relationships entered into on or after July 17, 2013. The adoption of ASU 2013-10 did not affect the Company's results of operations, cash flows, or financial position.
	Discontinued Operations In April 2014, the FASB issued an accounting standards update that raises the threshold for disposals to qualify as discontinued operations and allows companies to have significant continuing involvement with and continuing cash flows from or to the discontinued operation. It also requires additional disclosures for discontinued operations and new disclosures for individually material disposal transactions that do not meet the definition of a discontinued operation. This guidance will be effective for fiscal years beginning after December 15, 2014, and early adoption is permitted. The Company does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.
	Revenue Recognition In May 2014, the FASB issued ASU number 2014-09, “Revenue from Contracts with Customers (Topic 606) — to clarify and converge the revenue recognition principles under U.S. GAAP and IFRSs and to develop guidance that would streamline and enhance revenue recognition requirements while also providing a more robust framework for addressing revenue issues. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. Key provisions of the ASU involve a 5-step model specific to recognizing revenue derived from customer contracts. In addition, ASU 2014-09 provides implementation guidance on several other important topics, including the accounting for certain revenue-related costs. The adoption of ASU 2014-09 is effective for publicly traded business entities for annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Earlier application is not permitted. The Company is assessing the impact, if any, that the adoption of ASU 2014-09 may have on the Company's results of operations, cash flows, or financial position.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company used the following methods and assumptions in estimating fair value disclosure for financial instruments:
	Cash and cash equivalents The carrying amounts reported in the balance sheets approximate fair value due to the short-term maturity or variable rates of these instruments.
	Debt The carrying amount of fixed and variable-rate borrowings at June 30, 2014 approximates fair value estimated based on current market rates and credit spreads for similar debt instruments.
	Derivative instruments Fair value was determined based on the income approach and standard valuation techniques to convert future amounts to a single present amount and approximates the net gains and losses that would have been realized if the contracts had been settled at each period-end.
	The estimated fair values of the Company’s financial instruments are as follows:
		December 31, 2013				30-Jun-14
		Carrying		Fair		Carrying		Fair
		Value		Value		Value		Value
	Cash and cash equivalents	$	34,702	$	34,702	$	31,317	$	31,317
	Fixed-rate debt	25,552		25,552		12,235		12,397
	Variable-rate debt	504,122		504,112		495,761		495,761
	Derivative instruments - asset position	811		811		324		324
	Derivative instruments - liability position	104		104		78		78
	ASC 820, “Fair Value Measurement,” applies to all assets and liabilities that are being measured and reported at fair value on a recurring basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in generally accepted accounting principles by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:
		Level 1	Quoted market prices in active markets for identical assets or liabilities.
		Level 2	Observable market based inputs or unobservable inputs, including identical securities in inactive markets or similar securities in active markets, that are corroborated by market data.
		Level 3	Unobservable inputs that are not corroborated by market data.
	None of the Company’s instruments have transferred from one level to another.
	The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis by the above ASC 820 pricing levels as of December 31, 2013:
		Total		Quoted market		Significant other		Significant
				prices in active		observable  inputs		unobservable
				markets (Level 1)		(Level 2)		inputs (Level 3)
	Cash and cash equivalents	$	34,702	$	34,702	$	—	$	—
	Interest rate contracts - asset position	811				811
	Interest rate contracts - liability position	104		—		104		—
	The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis by the above ASC 820 pricing levels as of June 30, 2014:
		Total		Quoted market		Significant other		Significant
				prices in active		observable  inputs		unobservable
				markets (Level 1)		(Level 2)		inputs (Level 3)
	Cash and cash equivalents	$	31,317	$	31,317	$	—	$	—
	Interest rate contracts - asset position	324		—		324		—
	Interest rate contracts - liability position	78		—		78		—
	The Company’s derivative instruments are primarily pay-fixed, receive-variable interest rate swaps and caps based on the LIBOR swap rate. The Company has elected to use the income approach to value these derivatives, using observable Level 2 market expectations at measurement date and standard valuation techniques to convert future amounts to a single present amount assuming that participants are motivated, but not compelled to transact. Level 2 inputs for interest rate swap and cap valuations are limited to quoted prices for similar assets or liabilities in active markets (specifically futures contracts on LIBOR for the first two years) and inputs other than quoted prices that are observable for the asset or liability (specifically LIBOR cash and swap rates at commonly quoted intervals and implied volatilities for options). ASC 820 states that the fair value measurement of an asset or liability must reflect the nonperformance risk of the entity and the counterparty. Therefore, the impact of the counterparty’s creditworthiness and the Company’s creditworthiness has also been factored into the fair value measurement of the derivative instruments. For additional information please see Note 9 of the Notes to the Condensed Consolidated Financial Statements.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	Goodwill and Intangible Assets
	Changes in the carrying amount of goodwill are as follows:
	Balance at January 1, 2013	$	56,493
	Goodwill acquired during the period	—
	Impairment charges	—
	Adjustments to goodwill during the period	482
	Balance at December 31, 2013	56,975
	Goodwill acquired during the period	—
	Impairment charges	—
	Adjustments to goodwill during the period	—
	Balance at June 30, 2014	$	56,975
	Gross goodwill	$	231,219
	Accumulated impairment charges	(174,244		)
	Balance at June 30, 2014	$	56,975
	Intangible assets consisted of the following:
		31-Dec-13								30-Jun-14
		Gross Carrying			Accumulated			Intangible		Gross Carrying		Accumulated			Intangible
		Amount			Amortization			Assets, net		Amount		Amortization			Assets, net
	Amortizing intangible assets:
	Customer contracts	$	152,629		$	(86,584	)	$	66,045	$	152,889	$	(90,071	)	$	62,818
	Other	26,197			(20,868		)	5,329		26,240		(21,327		)	4,913
	Total amortizing intangible assets	$	178,826		$	(107,452	)	$	71,374	$	179,129	$	(111,398	)	$	67,731
	Intangible assets not subject to amortization							30,427							30,427
	Total other intangible assets							$	101,801						$	98,158
	In accordance with ASC 350, “Intangibles—Goodwill and Other,” the Company has elected to perform an annual impairment test in the fourth quarter for goodwill and indefinite life intangible assets based on the financial information as of September 30, or more frequently when an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company compares the fair value of its reporting units to its carrying amount to determine if there is potential impairment. The fair value of the reporting unit is determined by an income approach and a market capitalization approach. Significant management judgment is required in the forecasts of future operating results that are used in the income approach. The estimates that the Company has used are consistent with the plans and estimates that it uses to manage its business. The Company bases its fair value estimates on forecasted revenue and operating costs which include a number of factors including, but not limited to, securing new customers, retention of existing customers, growth in imaging and radiation oncology revenues and the impact of continued cost savings initiatives. However, it is possible that plans and estimates may change. Based on financial information as of June 30, 2014, impairment testing was not required during the six months ended June 30, 2014. Although the Company concluded that no impairment was present in its intangible assets in the six months of 2014, the Company intends to test its Goodwill and other intangibles assets for impairment during the fourth quarter of 2014, as described above.
	The Company uses the estimated useful life to amortize customer contracts, which is a weighted-average of 15 years. Other intangible assets subject to amortization are estimated to have a weighted-average useful life of six years. Amortization expense for intangible assets subject to amortization was $2,911 and $1,957 for the quarters ended June 30, 2013 and 2014, respectively, and $6,705 and $3,909 for the six months ended June 30, 2013 and 2014, respectively. The intangible assets not subject to amortization represent certificates of need and regulatory authority rights which have indefinite useful lives.
	Estimated annual amortization expense for each of the fiscal years ending December 31, is presented below:
	2014	$	3,875
	2015	7,061
	2016	6,059
	2017	5,621
	2018	5,260
	Thereafter	39,853

Other_Accrued_Liabilities

Other Accrued Liabilities	6 Months Ended
	Jun. 30, 2014
Other Accrued Liabilities [Abstract]	'
Other Accrued Liabilities	'
	Other Accrued Liabilities
	Other accrued liabilities consisted of the following:
		December 31,		30-Jun-14
		2013
	Accrued systems rental and maintenance costs	$	1,488	$	1,160
	Accrued site rental fees	999		852
	Accrued property and sales taxes payable	10,253		10,389
	Accrued self-insurance expense	1,635		1,635
	Deferred gain on sale of equipment	319		314
	Other accrued expenses	7,308		9,113
	Total	$	22,002	$	23,463

LongTerm_Debt_and_Senior_Subor

Long-Term Debt and Senior Subordinated Credit Facility	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Long-Term Debt and Senior Subordinated Credit Facility	'
	Senior Secured Term Loan Refinancing
	On June 3, 2013, the Company replaced its existing credit facility with a new senior secured credit agreement with Credit Suisse AG, Cayman Islands Branch, as administrative agent, and the other lenders party thereto (the “Credit Agreement”). The Credit Agreement consists of (i) a $340,000, six-year term loan facility, (ii) a $50,000, five-year revolving loan facility, including a $20,000 sublimit for letters of credit, (iii) uncommitted incremental loan facilities of $100,000 of revolving or term loans, plus an additional amount if our pro forma leverage ratio is less than or equal to 3.25, subject to receipt of lender commitments and satisfaction of specified conditions, and (iv) an $80,000 delayed draw term loan facility, which was required to be drawn within thirty days of June 3, 2013 and used for the redemption of $80,000 in aggregate principal amount of the Company's 8% Senior Notes due 2016 (the “Notes”).
	On July 3, 2013 the delayed draw term loan facility was utilized together with other available funds, of which the proceeds were used to redeem $80,000 of the Company's outstanding Notes. The delayed draw term loan facility converted into, and matched the terms of, the new $340,000 term loan facility.
	As a result of these transactions, during 2013, the Company recognized a loss on extinguishment totaling $17,069 for unamortized deferred financing costs and the discount related to the former credit facility. Additionally, $1,522 and $3,200 of expense was incurred for unamortized deferred costs and associated discount, and the related call premium, respectively, related to the redemption of the Notes.
	Borrowings under the Credit Agreement bear interest through maturity at a variable rate based upon, at the Company's option, either the London interbank offered rate ("LIBOR") or the base rate (which is the highest of the administrative agent’s prime rate, one-half of 1.00% in excess of the overnight federal funds rate, and 1.00% in excess of the one-month LIBOR rate), plus, in each case, an applicable margin. With respect to the term loan facilities, the applicable margin for LIBOR loans is 3.25% per annum, and with respect to the revolving loan facilities, the applicable margin for LIBOR loans ranges, based on the applicable leverage ratio, from 3.00% to 3.25% per annum, in each case, with a LIBOR floor of 1.00%. The applicable margin for base rate loans under the term loan facilities is 2.25% per annum and under the revolving loan facility ranges, based on the applicable leverage ratio, from 2.00% to 2.25% per annum. Prior to the refinancing of the term loan facilities, the applicable margin for base rate loans was 4.25% per annum and the applicable margin for revolving loans was 5.25% per annum, with a LIBOR floor of 2.00%. The Company is required to pay a commitment fee which ranges, based on the applicable leverage ratio, from 0.375% to 0.50% per annum on the undrawn portion available under the revolving loan facility and variable per annum fees with respect to outstanding letters of credit.
	During the first five and three-quarter years after the closing date, and including the full amount of the delayed draw term loan facility, the Company will be required to make quarterly amortization payments of the term loans in the amount of $1,050. The Company is also required to make mandatory prepayments of term loans under the Credit Agreement, subject to specified exceptions, from excess cash flow (as defined in the Credit Agreement), and with the proceeds of asset sales, debt issuances and specified other events.
	Obligations under the Credit Agreement are guaranteed by substantially all the Company's direct and indirect domestic subsidiaries. The obligations under the Credit Agreement and the guarantees are secured by a lien on substantially all tangible and intangible property, and by a pledge of all of the shares of stock and limited liability company interests of the Company's direct and indirect domestic subsidiaries, of which the Company now owns or later acquires more than a 50% interest, subject to limited exceptions.
	In addition to other covenants, the Credit Agreement places limits on the ability of the Company and its subsidiaries to declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transactions, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, transact with affiliates and alter the business conducted by the Company and its subsidiaries.
	The Credit Agreement also contains a leverage ratio covenant requiring the Company to maintain a maximum ratio of consolidated total debt to consolidated adjusted EBITDA expense that ranges from 4.95 to 1.00 to 4.30 to 1.00. For the quarter ended June 30, 2014, the Credit Agreement required a maximum leverage ratio of not more than 4.90 to 1.00. The Credit Agreement eliminated the interest coverage ratio covenant which the Company was subject to maintain prior to the refinancing. Failure to comply with the covenants in the Credit Agreement could permit the lenders under the Credit Agreement to declare all amounts borrowed under the Credit Agreement, together with accrued interest and fees, to be immediately due and payable, and to terminate all commitments under the Credit Agreement.
	In September 2013, the Company repurchased $8,772 in principal amount of its Notes in privately negotiated transactions. The Company immediately incurred $160 of expense related to unamortized deferred costs and associated discount, as well as $251 for the related call premium.
	On October 11, 2013, the Company entered into an amendment to the Credit Agreement with Credit Suisse AG, Cayman Islands Branch, as administrative agent, and the other lenders party thereto (the “First Amendment”). Pursuant to the First Amendment, the Company raised $70,000 in incremental term loan commitments to repurchase the remaining Notes. On December 2, 2013, the Company borrowed $70,000 of incremental term loans, and with such proceeds plus borrowings under its revolving line of credit and cash on hand, completed the redemption of all of its outstanding Notes on December 4, 2013. With the completion of this transaction including the redemption in full of the Notes, the Company expects to save approximately $5,000 in cash interest on an annualized basis.
	The incremental term loan was funded at 99.0% of principal amount and will mature on the same date as the existing term loan in June 2019. The incremental term loan will be converted to match all the terms of existing term loans upon funding in December. Interest on the incremental term loan will be calculated, at the Company's option, at a base rate plus a 2.25% margin or LIBOR plus a 3.25% margin, subject to a 1.00% LIBOR floor.
	As of June 30, 2014, there was $485,275 outstanding under the new term loan facility and $5,000 borrowings under the new revolving credit facility. As of June 30, 2014, the Company’s ratio of consolidated total debt to Consolidated Adjusted EBITDA calculated pursuant to the Credit Agreement was 3.55 to 1.00.
	During the first five and one half years after the closing date for the incremental term loan, the quarterly amortization payments of all term loans under the credit facility has increased to $1,225 from the previous amount of $1,050.
	The Company's obligations under the incremental term loans are guaranteed by substantially all of the Company’s direct and indirect domestic subsidiaries. The obligations under the incremental term loan and the guarantees are secured by a lien on substantially all of the Company’s tangible and intangible property, and by a pledge of all of the shares of stock and limited liability company interests of the Company’s direct and indirect domestic subsidiaries, of which the Company now owns or later acquires more than a 50% interest, subject to limited exceptions.

Derivatives

Derivatives

6 Months Ended

Jun. 30, 2014

Summary of Derivative Instruments [Abstract]

'

Derivatives

'

Derivatives

The Company accounts for derivative instruments and hedging activities in accordance with the provisions of ASC 815, “Derivatives and Hedging.” Management generally designates derivatives in a hedge relationship with the identified exposure on the date the Company enters into a derivative contract, as disclosed below. The Company has only executed derivative instruments that are economic hedges of exposures that can qualify in hedge relationships under ASC 815. The Company formally documents all relationships between hedging instruments and hedged items, as well as the risk-management objective and strategy for undertaking various hedge transactions. In this documentation, the Company specifically identifies the firm commitment or forecasted transaction that has been designated as a hedged item and states how the hedging instrument is expected to hedge the risks related to the hedged item. The Company formally assesses effectiveness of its hedging relationships, both at the hedge inception and on an ongoing basis, then measures and records ineffectiveness. The Company would discontinue hedge accounting prospectively (i) if it is determined that the derivative is no longer effective in offsetting change in the cash flows of a hedged item, (ii) when the derivative expires or is sold, terminated or exercised, (iii) because it is probable that the forecasted transaction will not occur, or (iv) if management determines that designation of the derivative as a hedge instrument is no longer appropriate. The Company’s derivatives are recorded on the balance sheet at their fair value. For additional information please see Note 5 of the Notes to the Condensed Consolidated Financial Statements. For derivatives accounted for as cash flow hedges, any effective unrealized gains or losses on fair value are included in comprehensive income (loss), net of tax, and any ineffective gains or losses are recognized in income immediately. Amounts recorded in comprehensive income (loss) are reclassified to earnings when the hedged item impacts earnings.

Cash Flow Hedges

Interest Rate Cash Flow Hedges

The Company has entered into multiple interest rate swap and cap agreements to hedge the future cash interest payments on portions of its variable rate bank debt. For the six months ended June 30, 2013 and 2014, the Company had interest rate swap and cap agreements to hedge approximately $162,300 and $258,500 of its variable rate bank debt, respectively, or 29.9% and 50.9% of total debt, respectively. Over the next twelve months, the Company expects to reclassify $40 from accumulated comprehensive loss to interest expense and other, net.

In the first quarter of 2010, the Company entered into three interest rate cap agreements, in accordance with Company policy, to avoid unplanned volatility in the income statement due to changes in the LIBOR interest rate environment. The interest rate cap agreements matured in February 2014, had a total notional amount of $150,000, and were de-designated as cash flow hedges associated with the Company’s variable rate bank debt in the fourth quarter of 2013.

In the second quarter of 2011, the Company acquired two interest rate swap agreements (the “USR Swaps”) as part of the acquisition of US Radiosurgery, LLC ("USR"). One of the USR Swaps, which matures in October 2015, had a notional amount of $1,394 as of June 30, 2014. Under the terms of this agreement, the Company receives one-month LIBOR and pays a fixed rate of 5.71%. The net effect of the hedge is to record interest expense at a fixed rate of 8.71%, as the underlying debt incurred interest based on one-month LIBOR plus 3.00%. The other USR Swap matured in April 2014. As a result of the acquisition of USR, the USR Swap was de-designated, hedge accounting was terminated and all further changes in the fair market value of the swap is being recorded in interest expense and other, net.

In the fourth quarter of 2012, the Company entered into an interest rate swap agreement in connection with equipment financing. The swap, which matures in December 2017, had a notional amount of $3,736 as of June 30, 2014. Under the terms of this agreement, the Company receives one-month LIBOR plus 2.50% and pays a fixed rate of 3.75%. The net effect of the hedge is to convert interest expense to a fixed rate of 3.75%, as the underlying debt incurred interest based on one-month LIBOR plus 2.50%.

In the first quarter of 2013, the Company entered into an interest rate swap agreement in connection with equipment financing. The swap, which matures in April 2018, had a notional amount of $3,370 as of June 30, 2014. Under the terms of this agreement, the Company receives one-month LIBOR plus 2.00% and pays a fixed rate of 2.873%. The net effect of the hedge is to convert interest expense to a fixed rate of 2.873%, as the underlying debt incurred interest based on one-month LIBOR plus 2.00%.

In the fourth quarter of 2013, the Company entered into five interest rate cap agreements ("2013 Caps"), in accordance with Company policy, to avoid unplanned volatility in the income statement due to changes in the LIBOR interest rate environment. The 2013 Caps, which mature in December 2016, had a notional amount of $250,000 and were designated as cash flow hedges of future cash interest payments associated with a portion of the Company’s variable rate bank debt. Under these arrangements, the Company has purchased a cap on LIBOR at 2.50%. The Company paid $815 to enter into the caps, which is being amortized through interest expense and other, net over the life of the agreements.

The Effect of Designated Derivative Instruments on the Statement of Operations

For the Three Months Ended June 30, 2013

Derivatives in Cash

Amount of Gain (Loss)

Location of Gain

Amount of Gain (Loss)

Location of Gain

Amount of Gain (Loss)

Flow Hedging

Recognized in OCI on

(Loss)

Reclassified from

(Loss) Recognized in

Recognized in Income

Relationships

Derivatives (Effective

Reclassified from

Accumulated OCI into

Income on Derivatives

on Derivatives

Portion)

Accumulated OCI into

Income (Effective

(Ineffective Portion)

(Ineffective Portion)

Income (Effective

Portion)

Portion)

Interest rate contracts

$

63

Interest expense and other, net

$

(221

)

Interest expense and other, net

$

—

The Effect of Designated Derivative Instruments on the Statement of Operations

For the Six Months Ended June 30, 2013

Derivatives in Cash

Amount of Gain (Loss)

Location of Gain

Amount of Gain (Loss)

Location of Gain

Amount of Gain (Loss)

Flow Hedging

Recognized in OCI on

(Loss)

Reclassified from

(Loss) Recognized in

Recognized in Income

Relationships

Derivatives (Effective

Reclassified from

Accumulated OCI into

Income on Derivatives

on Derivatives

Portion)

Accumulated OCI into

Income (Effective

(Ineffective Portion)

(Ineffective Portion)

Income (Effective

Portion)

Portion)

Interest rate contracts

$

30

Interest expense and other, net

$

(411

)

Interest expense and other, net

$

—

The Effect of Designated Derivative Instruments on the Statement of Operations

For the Three Months Ended June 30, 2014

Derivatives in Cash

Amount of Gain (Loss)

Location of Gain

Amount of Gain (Loss)

Location of Gain

Amount of Gain (Loss)

Flow Hedging

Recognized in OCI on

(Loss)

Reclassified from

(Loss) Recognized in

Recognized in Income

Relationships

Derivatives (Effective

Reclassified from

Accumulated OCI into

Income on Derivatives

on Derivatives

Portion)

Accumulated OCI into

Income (Effective

(Ineffective Portion)

(Ineffective Portion)

Income (Effective

Portion)

Portion)

Interest rate contracts

$

(375

)

Interest expense and other, net

$

8

Interest expense and other, net

$

—

The Effect of Designated Derivative Instruments on the Statement of Operations

For the Six Months Ended June 30, 2014

Derivatives in Cash

Amount of Gain (Loss)

Location of Gain

Amount of Gain (Loss)

Location of Gain

Amount of Gain (Loss)

Flow Hedging

Recognized in OCI on

(Loss)

Reclassified from

(Loss) Recognized in

Recognized in Income

Relationships

Derivatives (Effective

Reclassified from

Accumulated OCI into

Income on Derivatives

on Derivatives

Portion)

Accumulated OCI into

Income (Effective

(Ineffective Portion)

(Ineffective Portion)

Income (Effective

Portion)

Portion)

Interest rate contracts

$

(478

)

Interest expense and other, net

$

(126

)

Interest expense and other, net

$

(2

)

The Effect of Non-Designated Derivative Instruments on the Statement of Operations

For the Three Months Ended June 30, 2014

Derivatives in Cash Flow Hedging Relationships

Location of Gain (Loss) Recognized in Income on

Amount of Gain

Derivatives

(Loss) Recognized in

Income on

Derivatives

Interest rate contracts

Interest expense and other, net

$

(1

)

The Effect of Non-Designated Derivative Instruments on the Statement of Operations

For the Six Months Ended June 30, 2014

Derivatives in Cash Flow Hedging Relationships

Location of Gain (Loss) Recognized in Income on

Amount of Gain

Derivatives

(Loss) Recognized in

Income on

Derivatives

Interest rate contracts

Interest expense and other, net

$

(2

)

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	For the quarter and six months ended June 30, 2013, the Company recorded an income tax benefit of $7,195 and $7,333, or 35.7% and 32.3%, respectively, as a result of the Company’s effective tax rate applied to pretax loss. For the quarter and six months ended June 30, 2014, the Company recorded income tax expense of $1,802 and $3,309, or 39.3% and 41.2%, respectively, as a result of the Company’s effective tax rate applied to pretax income. The Company’s effective tax rate for the quarter and six months ended June 30, 2014 differed from the federal statutory rate principally as a result of state income taxes and permanent non-deductible tax items, including share-based payments, unrecognized tax benefits and other permanent differences.
	As of June 30, 2014, the Company has provided a liability for $304 of unrecognized tax benefits related to various federal and state income tax matters. The tax-effected amount that would reduce the Company’s effective income tax rate if recognized is $262.
	The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense. As of June 30, 2014, the Company had approximately $19 in accrued interest and penalties related to unrecognized tax benefits.
	The Company is subject to United States federal income tax as well as income tax of multiple state tax jurisdictions. The Company is currently open to audit under the statute of limitations by the Internal Revenue Service for the years ended December 31, 2010 through 2013. The Company’s and its subsidiaries’ state income tax returns are open to audit under the applicable statutes of limitations for the years ended December 31, 2009 through 2013. The Company does not anticipate a significant change to the total amount of unrecognized tax benefits within the next 12 months.

Earnings_Loss_Per_Common_Share

Earnings (Loss) Per Common Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings (Loss) per Common Share	'
	Earnings (Loss) Per Common Share
	Basic net income (loss) per share is computed utilizing the two-class method and is calculated based on the weighted-average number of common shares outstanding during the periods presented, excluding nonvested restricted stock units which do not contain nonforfeitable rights to dividend and dividend equivalents.
	Diluted net income (loss) per share is computed using the weighted-average number of common and common equivalent shares outstanding during the periods utilizing the two-class method for stock options, nonvested restricted stock and nonvested restricted stock units. Potentially dilutive securities are not considered in the calculation of net loss per share as their impact would be anti-dilutive.
	The following table sets forth the computation of basic and diluted earnings (loss) per share (amounts in thousands, except per share amounts):
		Quarter Ended					Six Months Ended
		June 30,					June 30,
		2013			2014		2013			2014
	Numerator:
	Net (loss) income attributable to Alliance HealthCare Services, Inc.	$	(12,964	)	$	2,784	$	(15,382	)	$	4,715
	Denominator:
	Weighted-average shares-basic	10,629			10,671		10,629			10,669
	Effect of dilutive securities:
	Employee stock options	—			183		—			203
	Weighted-average shares-diluted	10,629			10,854		10,629			10,872
	(Loss) income per common share attributable to Alliance HealthCare Services, Inc.:
	Basic	$	(1.22	)	$	0.26	$	(1.45	)	$	0.44
	Diluted	$	(1.22	)	$	0.26	$	(1.45	)	$	0.43
	Stock options excluded from the computation of diluted per share amounts:
	Weighted-average shares for which the exercise price exceeds average market price of common stock	291			132		310			134
	Average exercise price per share that exceeds average market price of common stock	$	35.31		$	44.22	$	34.55		$	44.25

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	In the normal course of business, the Company has made certain guarantees and indemnities, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain transactions. The Company indemnifies other parties, including customers, lessors, and parties to other transactions with the Company, with respect to certain matters. The Company has agreed to hold the other party harmless against losses arising from certain events as defined within the particular contract, which may include, for example, litigation or claims arising from a breach of representations or covenants. In addition, the Company has entered into indemnification agreements with its executive officers and directors and the Company's bylaws contain similar indemnification obligations. Under these arrangements, the Company is obligated to indemnify, to the fullest extent permitted under applicable law, its current or former officers and directors for various amounts incurred with respect to actions, suits or proceedings in which they were made, or threatened to be made, a party as a result of acting as an officer or director.
	It is not possible to determine the maximum potential amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. Historically, payments made related to these indemnifications have been immaterial. At June 30, 2014, the Company has determined that no liability is necessary related to these guarantees and indemnities.
	In June 2012, Pacific Coast Cardiology (“PCC”) d/b/a Pacific Coast Imaging, Emanuel Shaoulian, MD, Inc., and Michael M. Radin, MD, Inc. filed a lawsuit in California state court against the Company and other defendants. The complaint asserts a number of claims related to the Company’s decision not to purchase PCC in 2010, and also separately seeks a determination regarding an amount the Company contends is owed to it by PCC pursuant to a previous contractual arrangement. As of June 30, 2014, the Company had accrued a $1,200 liability based on a proposed settlement, which has been accepted by PCC, effectively settling this matter subject to court approval subsequent to June 30, 2014.
	On November 9, 2012, USR, a subsidiary of the Company, received a grand jury subpoena issued by the United States Attorney's Office for the Middle District of Tennessee seeking documents related to USR and its financial relationships with physicians and other healthcare providers. The Company and USR are cooperating fully with the inquiry. The Company is currently unable to predict the timing or outcome of this matter, however, it is not unusual for such matters to continue for a considerable period of time. Responding to this matter will require management's attention and likely result in significant legal expense. To management's knowledge, the federal government has not initiated any proceedings against the Company at this time.
	On March 27, 2013, the Company was served with a lawsuit filed in U.S. District Court for the Northern District of Mississippi by Superior MRI Services, Inc.  The plaintiff is an alleged successor in interest to a former local competitor, P&L Contracting, Inc.
	Plaintiff alleges the Company disregarded Mississippi Certificate of Need ("CON") rules and regulations by operating without obtaining the appropriate authority, and is seeking in excess of $1,000 in damages as well as requesting injunctive relief.  In January of 2014, the District Court dismissed plaintiff’s complaint on a number of procedural and substantive grounds. The plaintiff has appealed the District Court’s ruling and the Company will respond accordingly. The Company has not recorded an expense related to any potential damages in connection with this matter because any potential loss is not probable or reasonably estimable at this time.
	On June 14, 2013, Alliance Oncology, LLC, a subsidiary of the Company, filed a complaint against Harvard Vanguard Medical Associates, Inc. (“HVMA”) in the United States District Court for the District of Massachusetts, including several claims seeking damages resulting from HVMA’s early termination of a long-term services agreement between the two companies. HVMA filed an answer to Alliance Oncology’s complaint on August 27, 2013. Without specifying its alleged damages, HVMA also asserted several counterclaims in its answer. The Company filed its answer to HVMA’s counterclaims on October 4, 2013, and intends to vigorously defend against the claims asserted. The Company has not recorded an expense related to any potential damages in connection with this matter because any potential loss is not probable or reasonably estimable at this time.
	The Company from time to time is involved in routine litigation and regulatory matters incidental to the conduct of its business. The Company believes that resolution of such matters will not have a material adverse effect on its consolidated results of operations or financial position.

RelatedParty_Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related-Party Transactions	'
	Related-Party Transactions
	On April 16, 2007, Oaktree and MTS purchased 4,900,301 shares of the Company’s common stock. Upon completion of the transaction, Oaktree and MTS owned in the aggregate approximately 49.7% of the outstanding shares of common stock of the Company. At June 30, 2014, Oaktree and MTS owned in the aggregate approximately 50.9% of the outstanding shares of common stock of the Company. The Company does not pay management fees to Oaktree and MTS for their financial advisory services to the Company.
	Revenues from management agreements with unconsolidated equity investees were $2,276 and $2,241 during the quarters ended June 30, 2013 and 2014, respectively. Revenues from management agreements with unconsolidated equity investees were $4,520 and $4,562 during the six months ended June 30, 2013 and 2014 respectively. The Company provides services as part of its ongoing operations for and on behalf of the unconsolidated equity investees, which are included in the management agreement revenue, who reimburse the Company for the actual amount of the expenses incurred. The Company records the expenses as cost of revenues and the reimbursement as revenues in its condensed consolidated statements of operations and comprehensive income (loss). For the quarters ended June 30, 2013 and 2014, the amounts of the revenues and expenses were $1,814 and $1,783, respectively. For the six months ended June 30, 2013 and 2014, the amounts of the revenues and expenses were $3,623 and $3,687, respectively.
	On June 3, 2013, the Company replaced its existing credit facility with a new senior secured credit agreement with Credit Suisse AG, Cayman Islands Branch, as administrative agent, and the other lenders party thereto (the “Credit Agreement”). Of the other lenders, Oaktree funded approximately $40,476 of the $340,000 six-year term loan facility. In addition, as of July 3, 2013, Oaktree funded approximately $9,524 of the $80,000 delayed draw.
	On October 11, 2013, the Company obtained commitments from its current lenders with respect to a $70,000 incremental term loan under its Credit Agreement. On December 2, 2013 The Company borrowed $70,000 of the incremental term loans, and with such proceeds plus borrowings under its revolving line of credit and cash on hand, completed the redemption of all its outstanding Notes on December 4, 2013. Oaktree funded $10,000 of the $70,000 incremental term loan.

Investments_in_Unconsolidated_

Investments in Unconsolidated Investees	6 Months Ended
	Jun. 30, 2014
Investments in Unconsolidated Investees [Abstract]	'
Investments in Unconsolidated Investees	'
	Investments in Unconsolidated Investees
	The Company has direct ownership in three unconsolidated investees at June 30, 2014. The Company owns between 15% and 50% of these investees, and provides management services under agreements with these investees, expiring at various dates through 2025. All of these investees are accounted for under the equity method since the Company does not exercise control over the operations of these investees.
	During the quarter ended June 30, 2014, in accordance with ASC 323, “Investments—Equity Method and Joint Ventures,” the Company wrote off its remaining investment in one of its unconsolidated investees that was originally acquired in 2011. The impairment charge totaled $236 and is related to the closure of one cancer center in the second quarter of 2014 due to the expiration of one of its non-compete agreements with the affiliated oncology physician. Impairment charges related to this event were taken in the prior year for a physicians' referral network, trademarks, and professional services agreement, which were all written down to zero value.
	Set forth below are certain financial data for Alliance-HNI, LLC and Subsidiaries, one of the Company’s unconsolidated investees as of:
		December 31,		30-Jun-14
		2013
	Balance Sheet Data:
	Current assets	$	4,650	$	4,483
	Noncurrent assets	9,732		11,206
	Current liabilities	2,810		2,687
	Noncurrent liabilities	2,757		3,950
		Quarter Ended				Six Months Ended
		June 30,				June 30,
		2013		2014		2013		2014
	Operating Results:
	Revenues	$	4,583	$	4,225	$	9,081	$	8,331
	Expenses	2,341		2,266		4,318		4,821
	Net income	2,242		1,959		4,763		3,510
	Earnings from unconsolidated investee	1,106		979		2,382		1,755
	Set forth below are certain financial data for the aggregate of the Company’s unconsolidated investees, including Alliance-HNI, LLC and Subsidiaries as of:
		December 31,		30-Jun-14
		2013
	Balance Sheet Data:
	Current assets	$	7,188	$	6,823
	Noncurrent assets	11,058		12,326
	Current liabilities	3,569		3,548
	Noncurrent liabilities	3,382		4,328
		Quarter Ended				Six Months Ended
		June 30,				June 30,
		2013		2014		2013		2014
	Combined Operating Results:
	Revenues	$	7,272	$	6,765	$	14,009	$	13,196
	Expenses	3,315		3,210		6,906		6,745
	Net income	3,957		3,555		7,103		6,451
	Earnings from unconsolidated investees	1,409		1,242		2,951		2,240

Stockholders_Deficit

Stockholders' Deficit	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Deficit	'
	Stockholders’ Deficit
	The following table summarizes consolidated stockholders’ deficit, including noncontrolling interest.
											Additional		Accumulated						Stockholders’ Equity (Deficit)						Total
																			Attributable to
		Common Stock				Treasury Stock					Paid-In		Comprehensive			Accumulated			Alliance HealthCare			Noncontrolling			Stockholders’
		Shares		Amount		Shares		Amount			Capital		Income (Loss)			Deficit			Services, Inc.			Interest			Deficit
	Balance at January 1, 2014	10,667,136		$	524	(144,921	)	$	(2,998	)	$	23,521	$	(82	)	$	(204,709	)	$	(183,744	)	$	47,127		$	(136,617	)
	Exercise of stock options	67,657		1		—		—			705		—			—			706			—			706
	Forfeit of restricted stock	(26,272	)	—		—		—			—		—			—			—			—			—
	Issuance of restricted stock	—		—		(5,323	)	(140		)	—		—			—			(140		)	—			(140		)
	Share-based payment	—		—		—		—			710		—			—			710			—			710
	Unrealized loss on hedging transaction, net of tax	—		—		—		—			—		(215		)	—			(215		)	—			(215		)
	Net investments in subsidiaries	—		—		—		—			1,652		—			—			1,652			(8,916		)	(7,264		)
	Net income	—		—		—		—			—		—			4,715			4,715			7,085			11,800
	Balance at June 30, 2014	10,708,521		$	525	(150,244	)	$	(3,138	)	$	26,588	$	(297	)	$	(199,994	)	$	(176,316	)	$	45,296		$	(131,020	)

Segment_Information

Segment Information	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	Segment Information
	Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. In accordance with ASC 280, “Segment Reporting,” and based on the nature of the financial information that is received by the CODM, the Company operates in two operating segments, which are also its two reportable segments, Imaging and Radiation Oncology, based on similar economic and other characteristics.
	The Imaging segment is comprised of diagnostic imaging services including MRI, PET/CT and other imaging services. The Radiation Oncology segment is comprised of radiation oncology services. All intercompany revenues, expenses, payables and receivables are eliminated in consolidation and are not reviewed when evaluating segment performance. Each segment’s performance is evaluated based on Revenue, Segment Income and Net Income. The accounting policies of the segments are the same as those described in the summary of significant accounting policies in Note 1 of the Notes to the Consolidated Financial Statements on Form 10-K for the year ended December 31, 2013. Additionally, the Company does not consider its wholesale revenue and retail revenue sources to constitute separate operating segments as discrete financial information does not exist and is not provided to the CODM.
	The following table summarizes the Company’s revenue by segment:
		Quarter Ended						Six Months Ended
		June 30,						June 30,
		2013			2014			2013			2014
	Revenue
	Imaging	$	94,613		$	87,297		$	186,586		$	171,935
	Radiation Oncology	19,805			23,941			38,214			44,668
	Total	$	114,418		$	111,238		$	224,800		$	216,603
	The following are components of revenue:
		Quarter Ended						Six Months Ended
		June 30,						June 30,
		2013			2014			2013			2014
	Revenue
	MRI revenue	$	47,359		$	45,637		$	93,440		$	89,822
	PET/CT revenue	37,656			34,178			74,406			67,547
	Radiation Oncology revenue	19,805			23,941			38,214			44,668
	Other modalities and other revenue	9,598			7,482			18,740			14,566
	Total	$	114,418		$	111,238		$	224,800		$	216,603
	Segment income represents net income (loss) before income taxes; interest expense and other, net; amortization expense; depreciation expense; share-based payment; severance and related costs; noncontrolling interest in subsidiaries; restructuring charges; transaction costs; impairment charges, loss on extinguishment of debt, other non recurring charges, and non-cash charges. Segment income is the most frequently used measure of each segment’s performance by the CODM and is commonly used in setting performance goals. The following table summarizes the Company’s segment income:
		Quarter Ended						Six Months Ended
		June 30,						June 30,
		2013			2014			2013			2014
	Segment income
	Imaging	$	38,311		$	33,248		$	73,474		$	64,257
	Radiation Oncology	9,121			11,167			16,806			20,490
	Corporate / Other	(8,847		)	(7,746		)	(16,534		)	(15,126		)
	Total	$	38,585		$	36,669		$	73,746		$	69,621
	The reconciliation of Net (loss) income to total segment income is shown below:
		Quarter Ended						Six Months Ended
		June 30,						June 30,
		2013			2014			2013			2014
	Net (loss) income attributable to Alliance HealthCare Services, Inc.	$	(12,964	)	$	2,784		$	(15,382	)	$	4,715
	Income tax (benefit) expense	(7,195		)	1,802			(7,333		)	3,309
	Interest expense and other, net	11,053			6,124			23,325			12,362
	Amortization expense	2,911			1,957			6,705			3,909
	Depreciation expense	16,322			14,274			32,838			30,069
	Share-based payment (included in selling, general and administrative expenses)	329			376			735			710
	Severance and related costs	—			1,727			—			1,860
	Noncontrolling interest in subsidiaries	3,509			4,036			6,339			7,085
	Restructuring charges (Note 2)	1,890			1,563			3,363			2,455
	Transaction costs	—			937			80			939
	Impairment charges	4,867			236			4,867			236
	Loss on extinguishment of debt	17,069			—			17,069			—
	Other non-recurring charges (included in selling, general and administrative expenses	633			822			950			1,621
	Other non-cash charges (included in other income and expense, net)	161			31			190			351
	Total segment income	$	38,585		$	36,669		$	73,746		$	69,621
	Net income for the Imaging and Radiation Oncology segments does not include charges for interest expense, net of interest income, income taxes or certain selling, general and administrative expenses. These costs are charged against the Corporate / Other segment. The following table summarizes the Company’s net income (loss) by segment:
		Quarter Ended						Six Months Ended
		June 30,						June 30,
		2013			2014			2013			2014
	Net (loss) income
	Imaging	$	18,093		$	20,623		$	37,746		$	37,817
	Radiation Oncology	2,782			4,642			4,031			8,068
	Corporate / Other	(33,839		)	(22,481		)	(57,159		)	(41,170		)
	Total	$	(12,964	)	$	2,784		$	(15,382	)	$	4,715
	The following table summarizes the Company’s identifiable assets by segment:
		As of December 31,			As of June 30,
		2013			2014
	Identifiable assets
	Imaging	$	240,317		$	210,675
Radiation Oncology	158,216			156,067
Corporate / Other	91,314			101,343
Total	$	489,847		$	468,085
The following table summarizes the Company’s goodwill by segment:
	Imaging			Radiation			Corporate			Total
				Oncology			/ Other
Balance at January 1, 2013	$	41,684		$	14,809		$	—		$	56,493
Goodwill acquired during the period	—			—			—			—
Impairment charges	—			—			—			—
Adjustments to goodwill during the period	482			—			—			482
Balance at December 31, 2013	$	42,166		$	14,809		$	—		$	56,975
Goodwill acquired during the period	—			—			—			—
Impairment charges	—			—			—			—
Adjustments to goodwill during the period	—			—			—			—
Balance at June 30, 2014	$	42,166		$	14,809		$	—		$	56,975
Gross goodwill	$	196,508		$	34,711		$	—		$	231,219
Accumulated impairment charges	(154,342		)	(19,902		)	—			(174,244		)
Balance at June 30, 2014	$	42,166		$	14,809		$	—		$	56,975
Cash used for capital expenditures for the Imaging, Radiation Oncology and Corporate segments were $4,761, $19, and $2,741, respectively, for the quarter ended June 30, 2014. Capital expenditures in the Imaging, Radiation Oncology and Corporate segments were $3,468, $258 and $1,075, respectively, for the quarter ended June 30, 2013. Cash used for capital expenditures for the Imaging, Radiation Oncology and Corporate segments were $6,828, $19, and $6,409, respectively, for the six months ended June 30, 2014. Capital expenditures in the Imaging, Radiation Oncology and Corporate segments were $5,481, $671 and $4,205, respectively, for the six months ended June 30, 2013.

Basis_of_Presentation_Principl1

Basis of Presentation, Principles of Consolidation, and Use of Estimates (Policies)	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared by Alliance HealthCare Services, Inc. (the “Company”) in accordance with accounting principles generally accepted in the United States of America and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles (“GAAP”) for complete financial statements. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the quarter and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements for the year ended December 31, 2013.
Principles of Consolidation	'
	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company include the assets, liabilities, revenues and expenses of all majority-owned subsidiaries over which the Company exercises control. Intercompany transactions have been eliminated. The Company records noncontrolling interest related to its consolidated subsidiaries which are not wholly owned. Investments in non-consolidated investees are accounted for under the equity method.
Use of Estimates	'
	Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Share-based Payment	'
	The Company has adopted ASC 718, “Compensation—Stock Compensation,” and has elected to follow the alternative transition method as described in ASC 718 for computing its beginning additional paid-in capital pool. In addition, the Company treats the tax deductions from stock options as being realized when they reduce taxes payable in accordance with the principles and timing under the relevant tax law.
Derivatives	'
	The Company accounts for derivative instruments and hedging activities in accordance with the provisions of ASC 815, “Derivatives and Hedging.” Management generally designates derivatives in a hedge relationship with the identified exposure on the date the Company enters into a derivative contract, as disclosed below. The Company has only executed derivative instruments that are economic hedges of exposures that can qualify in hedge relationships under ASC 815. The Company formally documents all relationships between hedging instruments and hedged items, as well as the risk-management objective and strategy for undertaking various hedge transactions. In this documentation, the Company specifically identifies the firm commitment or forecasted transaction that has been designated as a hedged item and states how the hedging instrument is expected to hedge the risks related to the hedged item. The Company formally assesses effectiveness of its hedging relationships, both at the hedge inception and on an ongoing basis, then measures and records ineffectiveness. The Company would discontinue hedge accounting prospectively (i) if it is determined that the derivative is no longer effective in offsetting change in the cash flows of a hedged item, (ii) when the derivative expires or is sold, terminated or exercised, (iii) because it is probable that the forecasted transaction will not occur, or (iv) if management determines that designation of the derivative as a hedge instrument is no longer appropriate. The Company’s derivatives are recorded on the balance sheet at their fair value. For additional information please see Note 5 of the Notes to the Condensed Consolidated Financial Statements. For derivatives accounted for as cash flow hedges, any effective unrealized gains or losses on fair value are included in comprehensive income (loss), net of tax, and any ineffective gains or losses are recognized in income immediately. Amounts recorded in comprehensive income (loss) are reclassified to earnings when the hedged item impacts earnings.

ShareBased_Payment_Tables

Share-Based Payment (Tables)	6 Months Ended
	Jun. 30, 2014
Share-based Compensation [Abstract]	'
Weighted average assumptions for stock option awards	'
	The following weighted average assumptions were used in the estimated grant date fair value calculations for stock option awards:
		Six Months Ended June 30,
		2013		2014
	Risk free interest rate	1.06	%	1.83	%
	Expected dividend yield	—	%	—	%
	Expected stock price volatility	65.7	%	66.3	%
	Average expected life (in years)	5.99		6
Summary of stock option activity	'
	The following table summarizes the Company’s stock option activity:
		Number of		Weighted-		Weighted-	Aggregate
		Shares		Average		Average	Intrinsic
				Exercise Price		Remaining	Value
						Contractual
						Term
	Outstanding at December 31, 2013	803,617		$	20.83
	Granted	45,783		28.97
	Exercised	(67,657	)	6.32
	Canceled	(129,489	)	11.33
	Outstanding at June 30, 2014	652,254		$	21.64	6.26	$	6,124
	Vested and expected to vest in the future at June 30, 2014	638,467		$	21.6	6.28	$	6,053
	Exercisable at June 30, 2014	432,247		$	21.88	5.51	$	4,560
Summary of unvested stock option activity	'
	The following table summarizes the Company’s unvested stock option activity:
		Shares		Weighted-Average
				Grant-Date
				Fair Value
	Unvested at December 31, 2013	376,024		$	8.1
	Granted	45,783		17.56
	Vested	(83,654	)	5.61
	Canceled	(113,888	)	4.76
	Unvested at June 30, 2014	224,265		$	12.58
Summary of unvested restricted stock activity	'
	The following table summarizes the Company’s restricted stock activity:
		Shares		Weighted-Average
				Grant-Date
				Fair Value
	Unvested at January 1, 2012	273,308
	Granted to employees	38,075
	Granted to non-employee directors	19,469
	Vested	(119,968	)
	Canceled	(106,340	)
	Unvested at December 31, 2012	104,544
	Granted to employees	14,100
	Granted to non-employee directors	13,619
	Vested	(54,038	)
	Canceled	(7,334	)
	Unvested at December 31, 2013	70,891		$	7.01
	Granted to employees	25,000		30.33
	Granted to non-employee directors	—		—
	Vested	(31,000	)	30.33
	Canceled	(26,272	)	6.36
	Unvested at June 30, 2014	38,619		$	28.36

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Estimated fair values of financial instruments	'
	The estimated fair values of the Company’s financial instruments are as follows:
		December 31, 2013				30-Jun-14
		Carrying		Fair		Carrying		Fair
		Value		Value		Value		Value
	Cash and cash equivalents	$	34,702	$	34,702	$	31,317	$	31,317
	Fixed-rate debt	25,552		25,552		12,235		12,397
	Variable-rate debt	504,122		504,112		495,761		495,761
	Derivative instruments - asset position	811		811		324		324
	Derivative instruments - liability position	104		104		78		78
Financial instruments reported at fair value on a recurring basis	'
	The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis by the above ASC 820 pricing levels as of December 31, 2013:
		Total		Quoted market		Significant other		Significant
				prices in active		observable  inputs		unobservable
				markets (Level 1)		(Level 2)		inputs (Level 3)
	Cash and cash equivalents	$	34,702	$	34,702	$	—	$	—
	Interest rate contracts - asset position	811				811
	Interest rate contracts - liability position	104		—		104		—
	The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis by the above ASC 820 pricing levels as of June 30, 2014:
		Total		Quoted market		Significant other		Significant
				prices in active		observable  inputs		unobservable
				markets (Level 1)		(Level 2)		inputs (Level 3)
	Cash and cash equivalents	$	31,317	$	31,317	$	—	$	—
	Interest rate contracts - asset position	324		—		324		—
	Interest rate contracts - liability position	78		—		78		—

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Changes in the carrying amount of goodwill	'
	Changes in the carrying amount of goodwill are as follows:
	Balance at January 1, 2013	$	56,493
	Goodwill acquired during the period	—
	Impairment charges	—
	Adjustments to goodwill during the period	482
	Balance at December 31, 2013	56,975
	Goodwill acquired during the period	—
	Impairment charges	—
	Adjustments to goodwill during the period	—
	Balance at June 30, 2014	$	56,975
	Gross goodwill	$	231,219
	Accumulated impairment charges	(174,244		)
	Balance at June 30, 2014	$	56,975
Summary of intangible assets	'
	Intangible assets consisted of the following:
		31-Dec-13								30-Jun-14
		Gross Carrying			Accumulated			Intangible		Gross Carrying		Accumulated			Intangible
		Amount			Amortization			Assets, net		Amount		Amortization			Assets, net
	Amortizing intangible assets:
	Customer contracts	$	152,629		$	(86,584	)	$	66,045	$	152,889	$	(90,071	)	$	62,818
	Other	26,197			(20,868		)	5,329		26,240		(21,327		)	4,913
	Total amortizing intangible assets	$	178,826		$	(107,452	)	$	71,374	$	179,129	$	(111,398	)	$	67,731
	Intangible assets not subject to amortization							30,427							30,427
	Total other intangible assets							$	101,801						$	98,158
Estimated annual amortization expense	'
	Estimated annual amortization expense for each of the fiscal years ending December 31, is presented below:
	2014	$	3,875
	2015	7,061
	2016	6,059
	2017	5,621
	2018	5,260
	Thereafter	39,853

Other_Accrued_Liabilities_Tabl

Other Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Other Accrued Liabilities [Abstract]	'
Components of other accrued liabilities	'
	Other accrued liabilities consisted of the following:
		December 31,		30-Jun-14
		2013
	Accrued systems rental and maintenance costs	$	1,488	$	1,160
	Accrued site rental fees	999		852
	Accrued property and sales taxes payable	10,253		10,389
	Accrued self-insurance expense	1,635		1,635
	Deferred gain on sale of equipment	319		314
	Other accrued expenses	7,308		9,113
	Total	$	22,002	$	23,463

LongTerm_Debt_and_Senior_Subor1

Long-Term Debt and Senior Subordinated Credit Facility (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Components of long-term debt	'
	Long-term debt consisted of the following:
		December 31,			30-Jun-14
		2013
	Term loan facility	$	487,725		$	485,275
	Discount on term loan facility	(2,603		)	(2,381		)
	Revolving credit facility	19,000			5,000
	Equipment debt	25,552			20,102
	Long-term debt, including current portion	529,674			507,996
	Less current portion	15,066			13,292
	Long-term debt	$	514,608		$	494,704

Derivatives_Tables

Derivatives (Tables)

6 Months Ended

Jun. 30, 2014

Summary of Derivative Instruments [Abstract]

'

Effect of Derivative Instruments on the Statement of Operations

'

The Effect of Designated Derivative Instruments on the Statement of Operations

For the Three Months Ended June 30, 2014

Derivatives in Cash

Amount of Gain (Loss)

Location of Gain

Amount of Gain (Loss)

Location of Gain

Amount of Gain (Loss)

Flow Hedging

Recognized in OCI on

(Loss)

Reclassified from

(Loss) Recognized in

Recognized in Income

Relationships

Derivatives (Effective

Reclassified from

Accumulated OCI into

Income on Derivatives

on Derivatives

Portion)

Accumulated OCI into

Income (Effective

(Ineffective Portion)

(Ineffective Portion)

Income (Effective

Portion)

Portion)

Interest rate contracts

$

(375

)

Interest expense and other, net

$

8

Interest expense and other, net

$

—

The Effect of Designated Derivative Instruments on the Statement of Operations

For the Six Months Ended June 30, 2014

Derivatives in Cash

Amount of Gain (Loss)

Location of Gain

Amount of Gain (Loss)

Location of Gain

Amount of Gain (Loss)

Flow Hedging

Recognized in OCI on

(Loss)

Reclassified from

(Loss) Recognized in

Recognized in Income

Relationships

Derivatives (Effective

Reclassified from

Accumulated OCI into

Income on Derivatives

on Derivatives

Portion)

Accumulated OCI into

Income (Effective

(Ineffective Portion)

(Ineffective Portion)

Income (Effective

Portion)

Portion)

Interest rate contracts

$

(478

)

Interest expense and other, net

$

(126

)

Interest expense and other, net

$

(2

)

The Effect of Non-Designated Derivative Instruments on the Statement of Operations

For the Three Months Ended June 30, 2014

Derivatives in Cash Flow Hedging Relationships

Location of Gain (Loss) Recognized in Income on

Amount of Gain

Derivatives

(Loss) Recognized in

Income on

Derivatives

Interest rate contracts

Interest expense and other, net

$

(1

)

The Effect of Non-Designated Derivative Instruments on the Statement of Operations

For the Six Months Ended June 30, 2014

Derivatives in Cash Flow Hedging Relationships

Location of Gain (Loss) Recognized in Income on

Amount of Gain

Derivatives

(Loss) Recognized in

Income on

Derivatives

Interest rate contracts

Interest expense and other, net

$

(2

)

Earnings_Loss_Per_Common_Share1

Earnings (Loss) Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Computation of basic and diluted loss per share	'
	The following table sets forth the computation of basic and diluted earnings (loss) per share (amounts in thousands, except per share amounts):
		Quarter Ended					Six Months Ended
		June 30,					June 30,
		2013			2014		2013			2014
	Numerator:
	Net (loss) income attributable to Alliance HealthCare Services, Inc.	$	(12,964	)	$	2,784	$	(15,382	)	$	4,715
	Denominator:
	Weighted-average shares-basic	10,629			10,671		10,629			10,669
	Effect of dilutive securities:
	Employee stock options	—			183		—			203
	Weighted-average shares-diluted	10,629			10,854		10,629			10,872
	(Loss) income per common share attributable to Alliance HealthCare Services, Inc.:
	Basic	$	(1.22	)	$	0.26	$	(1.45	)	$	0.44
	Diluted	$	(1.22	)	$	0.26	$	(1.45	)	$	0.43
	Stock options excluded from the computation of diluted per share amounts:
	Weighted-average shares for which the exercise price exceeds average market price of common stock	291			132		310			134
	Average exercise price per share that exceeds average market price of common stock	$	35.31		$	44.22	$	34.55		$	44.25

Investments_in_Unconsolidated_1

Investments in Unconsolidated Investees (Tables)	6 Months Ended
	Jun. 30, 2014
Alliance-HNI, LLC and Subsidiaries	'
Schedule Of Equity Method Investments [Line Items]	'
Schedule of financial data of unconsolidated investees, Balance Sheet Data	'
	Set forth below are certain financial data for Alliance-HNI, LLC and Subsidiaries, one of the Company’s unconsolidated investees as of:
		December 31,		30-Jun-14
		2013
	Balance Sheet Data:
	Current assets	$	4,650	$	4,483
	Noncurrent assets	9,732		11,206
	Current liabilities	2,810		2,687
	Noncurrent liabilities	2,757		3,950
Schedule of financial data of unconsolidated investees, Combined Operating Results	'
		Quarter Ended				Six Months Ended
		June 30,				June 30,
		2013		2014		2013		2014
	Operating Results:
	Revenues	$	4,583	$	4,225	$	9,081	$	8,331
	Expenses	2,341		2,266		4,318		4,821
	Net income	2,242		1,959		4,763		3,510
	Earnings from unconsolidated investee	1,106		979		2,382		1,755
Unconsolidated Investees, Including Alliance-HNI, LLC and Subsidiaries and Austin Cyberknife	'
Schedule Of Equity Method Investments [Line Items]	'
Schedule of financial data of unconsolidated investees, Balance Sheet Data	'
	Set forth below are certain financial data for the aggregate of the Company’s unconsolidated investees, including Alliance-HNI, LLC and Subsidiaries as of:
		December 31,		30-Jun-14
		2013
	Balance Sheet Data:
	Current assets	$	7,188	$	6,823
	Noncurrent assets	11,058		12,326
	Current liabilities	3,569		3,548
	Noncurrent liabilities	3,382		4,328
Schedule of financial data of unconsolidated investees, Combined Operating Results	'
		Quarter Ended				Six Months Ended
		June 30,				June 30,
		2013		2014		2013		2014
	Combined Operating Results:
	Revenues	$	7,272	$	6,765	$	14,009	$	13,196
	Expenses	3,315		3,210		6,906		6,745
	Net income	3,957		3,555		7,103		6,451
	Earnings from unconsolidated investees	1,409		1,242		2,951		2,240

Stockholders_Deficit_Tables

Stockholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Summary of stockholders' deficit, including noncontrolling interest	'
	The following table summarizes consolidated stockholders’ deficit, including noncontrolling interest.
											Additional		Accumulated						Stockholders’ Equity (Deficit)						Total
																			Attributable to
		Common Stock				Treasury Stock					Paid-In		Comprehensive			Accumulated			Alliance HealthCare			Noncontrolling			Stockholders’
		Shares		Amount		Shares		Amount			Capital		Income (Loss)			Deficit			Services, Inc.			Interest			Deficit
	Balance at January 1, 2014	10,667,136		$	524	(144,921	)	$	(2,998	)	$	23,521	$	(82	)	$	(204,709	)	$	(183,744	)	$	47,127		$	(136,617	)
	Exercise of stock options	67,657		1		—		—			705		—			—			706			—			706
	Forfeit of restricted stock	(26,272	)	—		—		—			—		—			—			—			—			—
	Issuance of restricted stock	—		—		(5,323	)	(140		)	—		—			—			(140		)	—			(140		)
	Share-based payment	—		—		—		—			710		—			—			710			—			710
	Unrealized loss on hedging transaction, net of tax	—		—		—		—			—		(215		)	—			(215		)	—			(215		)
	Net investments in subsidiaries	—		—		—		—			1,652		—			—			1,652			(8,916		)	(7,264		)
	Net income	—		—		—		—			—		—			4,715			4,715			7,085			11,800
	Balance at June 30, 2014	10,708,521		$	525	(150,244	)	$	(3,138	)	$	26,588	$	(297	)	$	(199,994	)	$	(176,316	)	$	45,296		$	(131,020	)

Segment_Information_Tables

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Summary of revenue by segment	'
	The following table summarizes the Company’s revenue by segment:
		Quarter Ended						Six Months Ended
		June 30,						June 30,
		2013			2014			2013			2014
	Revenue
	Imaging	$	94,613		$	87,297		$	186,586		$	171,935
	Radiation Oncology	19,805			23,941			38,214			44,668
	Total	$	114,418		$	111,238		$	224,800		$	216,603
	The following are components of revenue:
		Quarter Ended						Six Months Ended
		June 30,						June 30,
		2013			2014			2013			2014
	Revenue
	MRI revenue	$	47,359		$	45,637		$	93,440		$	89,822
	PET/CT revenue	37,656			34,178			74,406			67,547
	Radiation Oncology revenue	19,805			23,941			38,214			44,668
	Other modalities and other revenue	9,598			7,482			18,740			14,566
	Total	$	114,418		$	111,238		$	224,800		$	216,603
Summary of segment income	'
	The following table summarizes the Company’s segment income:
		Quarter Ended						Six Months Ended
		June 30,						June 30,
		2013			2014			2013			2014
	Segment income
	Imaging	$	38,311		$	33,248		$	73,474		$	64,257
	Radiation Oncology	9,121			11,167			16,806			20,490
	Corporate / Other	(8,847		)	(7,746		)	(16,534		)	(15,126		)
	Total	$	38,585		$	36,669		$	73,746		$	69,621
Reconciliation of Net loss to total segment income	'
	The reconciliation of Net (loss) income to total segment income is shown below:
		Quarter Ended						Six Months Ended
		June 30,						June 30,
		2013			2014			2013			2014
	Net (loss) income attributable to Alliance HealthCare Services, Inc.	$	(12,964	)	$	2,784		$	(15,382	)	$	4,715
	Income tax (benefit) expense	(7,195		)	1,802			(7,333		)	3,309
	Interest expense and other, net	11,053			6,124			23,325			12,362
	Amortization expense	2,911			1,957			6,705			3,909
	Depreciation expense	16,322			14,274			32,838			30,069
	Share-based payment (included in selling, general and administrative expenses)	329			376			735			710
	Severance and related costs	—			1,727			—			1,860
	Noncontrolling interest in subsidiaries	3,509			4,036			6,339			7,085
	Restructuring charges (Note 2)	1,890			1,563			3,363			2,455
	Transaction costs	—			937			80			939
	Impairment charges	4,867			236			4,867			236
	Loss on extinguishment of debt	17,069			—			17,069			—
	Other non-recurring charges (included in selling, general and administrative expenses	633			822			950			1,621
	Other non-cash charges (included in other income and expense, net)	161			31			190			351
	Total segment income	$	38,585		$	36,669		$	73,746		$	69,621
Summary of net income (loss) by segment	'
	The following table summarizes the Company’s net income (loss) by segment:
		Quarter Ended						Six Months Ended
		June 30,						June 30,
		2013			2014			2013			2014
	Net (loss) income
	Imaging	$	18,093		$	20,623		$	37,746		$	37,817
	Radiation Oncology	2,782			4,642			4,031			8,068
	Corporate / Other	(33,839		)	(22,481		)	(57,159		)	(41,170		)
	Total	$	(12,964	)	$	2,784		$	(15,382	)	$	4,715
Summary of Company's identifiable assets by segment	'
	The following table summarizes the Company’s identifiable assets by segment:
		As of December 31,			As of June 30,
		2013			2014
	Identifiable assets
	Imaging	$	240,317		$	210,675
	Radiation Oncology	158,216			156,067
	Corporate / Other	91,314			101,343
	Total	$	489,847		$	468,085
Summary of company's goodwill by segment	'
	The following table summarizes the Company’s goodwill by segment:
		Imaging			Radiation			Corporate			Total
					Oncology			/ Other
	Balance at January 1, 2013	$	41,684		$	14,809		$	—		$	56,493
	Goodwill acquired during the period	—			—			—			—
	Impairment charges	—			—			—			—
	Adjustments to goodwill during the period	482			—			—			482
	Balance at December 31, 2013	$	42,166		$	14,809		$	—		$	56,975
	Goodwill acquired during the period	—			—			—			—
	Impairment charges	—			—			—			—
	Adjustments to goodwill during the period	—			—			—			—
	Balance at June 30, 2014	$	42,166		$	14,809		$	—		$	56,975
	Gross goodwill	$	196,508		$	34,711		$	—		$	231,219
	Accumulated impairment charges	(154,342		)	(19,902		)	—			(174,244		)
	Balance at June 30, 2014	$	42,166		$	14,809		$	—		$	56,975

Transactions_Restructuring_Pla

Transactions (Restructuring Plan) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring charges	$1,563	$1,890	$2,455	$3,363
Selling, general and administrative expenses	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring charges	'	'	1,640	2,608
Severance and related costs	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring charges	'	'	1,860	646
Cost of revenues, excluding depreciation and amortization	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring charges	'	'	$815	$109

ShareBased_Payment_Weighted_Av

Share-Based Payment (Weighted Average Assumptions for Fair Value of Stock Options) (Details)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Weighted average assumptions for stock option awards	'	'
Risk free interest rate	1.83%	1.06%
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	66.30%	65.70%
Average expected life (in years)	'6 years	'5 years 11 months 26 days

ShareBased_Payment_Stock_Optio

Share-Based Payment (Stock Option Activity) (Details) (USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Summary of stock option activity	'	'
Begining balance (shares)	803,617	'
Granted (shares)	45,783	'
Exercised (shares)	-67,657	-3,665
Canceled (shares)	-129,489	'
Ending balance (shares)	652,254	'
Vested and expected to vest (shares)	638,467	'
Exercisable (shares)	432,247	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'
Beginning balance, weighted-average exercise price (dollars per share)	$20.83	'
Granted, weighted-average exercise price (dollars per share)	$28.97	'
Exercised, weighted-average exercise price (dollars per share)	$6.32	'
Canceled, weighted-average exercise price (dollars per share)	$11.33	'
Ending balance, weighted-average exercise price (dollars per share)	$21.64	'
Vested and expected to vest, weighted-average exercise price (dollars per share)	$21.60	'
Exercisable, weighted-average exercise price (dollars per share)	$21.88	'
Outstanding, weighted-average remaining contractual term (in years)	'6 years 3 months 4 days	'
Vested and expected to vest, weighted-average remaining contractual term (in years)	'6 years 3 months 12 days	'
Exercisable, weighted-average remaining contractual term (in years)	'5 years 6 months 4 days	'
Outstanding, aggregate intrinsic value	$6,124	'
Vested and expected to vest, aggregate intrinsic value	6,053	'
Exercisable, aggregate intrinsic value	$4,560	'

ShareBased_Payment_Unvested_St

Share-Based Payment (Unvested Stock Activity) (Details) (USD $)

12 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Unvested stock option

Restricted stock

Restricted stock

Restricted stock

Employees

Employees

Employees

Non-employee directors

Non-employee directors

Non-employee directors

Restricted stock

Restricted stock

Summary of unvested stock option activity

'

'

'

'

'

'

'

'

'

'

'

'

Beginning balance, unvested shares (shares)

104,544

273,308

376,024

'

70,891

'

'

'

'

'

'

'

Granted, unvested share (shares)

'

'

45,783

25,000

'

'

14,100

38,075

25,000

13,619

19,469

0

Vested, unvested share (shares)

-54,038

-119,968

-83,654

'

-31,000

'

'

'

'

'

'

'

Canceled, unvested share (shares)

-7,334

-106,340

-113,888

'

-26,272

'

'

'

'

'

'

'

Ending balance, unvested shares (shares)

'

104,544

224,265

38,619

38,619

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

Beginning balance, unvested shares, weighted-average grant-date fair value (dollars per share)

'

'

$8.10

'

$7.01

'

'

'

'

'

'

'

Granted, unvested shares, weighted-average grant-date fair value (dollars per share)

'

'

$17.56

'

'

$6.38

'

'

$30.33

'

'

$0

Vested, unvested shares, weighted-average grant-date fair value (dollars per share)

'

'

$5.61

'

$30.33

'

'

'

'

'

'

'

Canceled, unvested shares, weighted-average grant-date fair value (dollars per share)

'

'

$4.76

'

$6.36

'

'

'

'

'

'

'

Ending balance, unvested shares, weighted-average grant-date fair value (dollars per share)

'

'

$12.58

$28.36

$28.36

'

'

'

'

'

'

'

ShareBased_Payment_Textual_Det

Share-Based Payment (Textual) (Details) (USD $)

6 Months Ended

12 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

In Thousands, except Share data, unless otherwise specified

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Nov. 30, 1999

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Employees

Employees

Non-employee directors

Non-employee directors

Non-Employee Director Serving as Member of Audit Committee [Member]

Non-Employee Director Serving as Chairman of Audit Committee [Member]

Non-Employee Director Serving As Member of Nominating Committee, Compensation Committee, and Strategy and Finance Committee [Member]

Non-Employee Director Serving as Chairman of Strategy and Finance Committee [Member]

Directors' Deferred Compensation Plan [Member]

Directors' Deferred Compensation Plan [Member]

Directors' Deferred Compensation Plan [Member]

Directors' Deferred Compensation Plan [Member]

Directors' Deferred Compensation Plan [Member]

Restricted Stock Awards

Restricted Stock Awards

Restricted Stock Awards

Restricted Stock Awards

Restricted Stock Awards

Restricted Stock Awards

Restricted Stock Awards

Restricted Stock Awards

Restricted Stock Awards

Restricted Stock Awards

Restricted Stock Awards

Options granted prior to January 1, 2008

Minimum

Maximum

Non-employee directors

Non-employee directors

Unaffiliated directors

Unaffiliated directors

Affiliated Director [Member]

Employees

Non-employee directors

Unaffiliated directors

Unaffiliated directors

Board of Directors Chairman [Member]

Cliff vest after one year

Time option

Options granted after January 1, 2008

Options granted after January 1, 2008

1999 Equity Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Compensation Arrangement with Individual, Fair Value of Shares Expected To Be Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$140

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares available for options and awards (shares)

550,605

'

'

'

2,205,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options term (years)

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options, typically vesting each year from the date of grant (percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.30%

'

'

'

'

'

'

'

'

'

Vesting period (years)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'3 years

'

'

'

'1 year

'

'1 year

'

'3 years

'4 years

Options accelerated due to employment agreements vesting (shares)

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accelerated options vested during period (shares)

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Subsequent stock options, vesting after one year (percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

Subsequent stock options, vesting after two year (percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

Subsequent stock options, vesting after three year (percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

'

'

Subsequent stock options, vesting after four year (percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

'

'

Subsequent stock options, vesting after five year (percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

'

'

Weighted average grant date fair value (dollars per share)

$17.56

$7.42

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options exercised (shares)

67,657

3,665

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total unrecognized fair value related to unvested stock options

2,074

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

735

'

349

'

'

'

'

'

'

Recognized weighted-average period (years)

'2 years 6 months 0 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 9 months 21 days

'

'6 months

'

'

'

'

'

'

Total fair value of shares vested

469

1,029

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of awards to non-employees (shares)

'

'

'

'

'

14,100

38,075

13,619

19,469

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

25,000

0

'

'

'

'

'

'

'

Share-based payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

245

251

'

'

'

'

'

'

'

'

'

'

'

Shares forfeited during period (shares)

'

'

7,334

106,340

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26,272

'

'

'

'

'

'

'

'

'

'

'

'

Granted, unvested shares, weighted-average grant-date fair value (dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.38

'

'

$30.33

$0

'

'

'

'

'

'

'

Common stock

525

'

524

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Noninterest Expense Directors Fees

'

'

'

'

'

'

'

'

'

15

30

5

25

40

40

'

40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40

'

'

'

'

'

'

'

'

'

'

138

'

'

'

'

Additional Noninterest Expense Directors Fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Officers' Compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$140

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Estimated Fair Value of Financial Instruments) (Details) (Fair Value, Measurements, Recurring, USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Estimated fair values of financial instruments	'	'
Cash and cash equivalents	$31,317	$34,702
Carrying Value	'	'
Estimated fair values of financial instruments	'	'
Cash and cash equivalents	31,317	34,702
Fixed-rate debt	12,235	25,552
Variable-rate debt	495,761	504,122
Derivative instruments - asset position	324	811
Derivative instruments - liability position	78	104
Fair Value	'	'
Estimated fair values of financial instruments	'	'
Cash and cash equivalents	31,317	34,702
Fixed-rate debt	12,397	25,552
Variable-rate debt	495,761	504,112
Derivative instruments - asset position	324	811
Derivative instruments - liability position	$78	$104

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments (Summary of Valuation of Financial Instruments Reported at Fair Value on a Recurring Basis by Pricing Level) (Details) (Recurring basis, USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Financial instruments reported at fair value on a recurring basis	'	'
Cash and cash equivalents	$31,317	$34,702
Interest rate contracts	'	'
Financial instruments reported at fair value on a recurring basis	'	'
Interest rate contracts - asset position	324	811
Interest rate contracts - liability position	78	104
Quoted market prices in active markets (Level 1)	'	'
Financial instruments reported at fair value on a recurring basis	'	'
Cash and cash equivalents	31,317	34,702
Quoted market prices in active markets (Level 1) | Interest rate contracts	'	'
Financial instruments reported at fair value on a recurring basis	'	'
Interest rate contracts - asset position	0	'
Interest rate contracts - liability position	0	0
Significant other observable inputs (Level 2)	'	'
Financial instruments reported at fair value on a recurring basis	'	'
Cash and cash equivalents	0	0
Significant other observable inputs (Level 2) | Interest rate contracts	'	'
Financial instruments reported at fair value on a recurring basis	'	'
Interest rate contracts - asset position	324	811
Interest rate contracts - liability position	78	104
Significant unobservable inputs (Level 3)	'	'
Financial instruments reported at fair value on a recurring basis	'	'
Cash and cash equivalents	0	0
Significant unobservable inputs (Level 3) | Interest rate contracts	'	'
Financial instruments reported at fair value on a recurring basis	'	'
Interest rate contracts - asset position	0	'
Interest rate contracts - liability position	$0	$0

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Goodwill Rollforward) (Details) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Changes in the Carrying Amount of Goodwill	'	'
Beginning balance	$56,975	$56,493
Goodwill acquired during the period	0	0
Impairment charges	0	0
Adjustments to goodwill during the period	0	482
Ending balance	56,975	56,975
Gross goodwill	231,219	'
Accumulated impairment charges	($174,244)	'

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets (Components of Intangible Assets) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Amortizing intangible assets:	'	'
Gross Carrying Amount	$179,129	$178,826
Accumulated Amortization	-111,398	-107,452
Intangible Assets, net	67,731	71,374
Intangible assets not subject to amortization	30,427	30,427
Total other intangible assets	98,158	101,801
Customer contracts	'	'
Amortizing intangible assets:	'	'
Gross Carrying Amount	152,889	152,629
Accumulated Amortization	-90,071	-86,584
Intangible Assets, net	62,818	66,045
Other	'	'
Amortizing intangible assets:	'	'
Gross Carrying Amount	26,240	26,197
Accumulated Amortization	-21,327	-20,868
Intangible Assets, net	$4,913	$5,329

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets (Estimated Annual Amortization Expense) (Details) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Estimated annual amortization expense	'
2014	$3,875
2015	7,061
2016	6,059
2017	5,621
2018	5,260
Thereafter	$39,853

Goodwill_and_Intangible_Assets5

Goodwill and Intangible Assets (Textual) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Goodwill and Intangible Assets (Textual) [Abstract]	'	'	'	'
Amortization expense	$1,957	$2,911	$3,909	$6,705
Customer contracts	'	'	'	'
Goodwill and Intangible Assets (Textual) [Abstract]	'	'	'	'
Weighted-average estimated useful life of amortization intangible assets (years)	'	'	'15 years	'
Other intangible assets	'	'	'	'
Goodwill and Intangible Assets (Textual) [Abstract]	'	'	'	'
Weighted-average estimated useful life of amortization intangible assets (years)	'	'	'6 years	'

Other_Accrued_Liabilities_Deta

Other Accrued Liabilities (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Components of other accrued liabilities	'	'
Accrued systems rental and maintenance costs	$1,160	$1,488
Accrued site rental fees	852	999
Accrued property and sales taxes payable	10,389	10,253
Accrued self-insurance expense	1,635	1,635
Deferred gain on sale of equipment	314	319
Other accrued expenses	9,113	7,308
Total	$23,463	$22,002

LongTerm_Debt_and_Senior_Subor2

Long-Term Debt and Senior Subordinated Credit Facility - Schedule of Long-term Debt (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Long-term debt, including current portion	$507,996	$529,674
Current portion of long-term debt	13,292	15,066
Long-term debt	494,704	514,608
Equipment Debt [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt, gross	20,102	25,552
Revolving Credit Facility	'	'
Debt Instrument [Line Items]	'	'
Revolving credit facility	5,000	19,000
Term Loan Facility	'	'
Debt Instrument [Line Items]	'	'
Long-term debt, gross	485,275	487,725
Discount on term loan facility	$2,381	$2,603

LongTerm_Debt_and_Senior_Subor3

Long-Term Debt and Senior Subordinated Credit Facility (Details) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

6 Months Ended

6 Months Ended

0 Months Ended

0 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 03, 2013

Jul. 03, 2013

Jun. 03, 2013

Sep. 30, 2013

Jun. 30, 2014

Oct. 11, 2013

Dec. 02, 2013

Nov. 07, 2013

Jun. 03, 2013

Jun. 03, 2013

Dec. 31, 2013

Jun. 03, 2013

Jun. 30, 2014

Jun. 03, 2013

Jun. 03, 2013

Jun. 30, 2014

Jun. 03, 2013

Jun. 30, 2014

Jun. 03, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 03, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 03, 2013

Jun. 03, 2013

Jun. 03, 2013

Oct. 11, 2013

Jun. 03, 2013

Jun. 03, 2013

Jun. 03, 2013

Jun. 03, 2013

Jun. 03, 2013

Jun. 03, 2013

Jun. 03, 2013

Oct. 11, 2013

Jun. 03, 2013

Jun. 03, 2013

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

Maximum

Maximum

Maximum

Maximum

Maximum

Minimum

Minimum

Minimum

Minimum

LIBOR

LIBOR

LIBOR

LIBOR

LIBOR

LIBOR

LIBOR

Base Rate

Base Rate

Base Rate

Base Rate

Base Rate

Base Rate

Base Rate

Term Loan Facility

Term Loan Facility

Term Loan Facility

Term Loan Facility

Committed Incremental Term Loan

Committed Incremental Term Loan

Committed Incremental Term Loan

Delayed Draw

Senior notes

Senior notes

Revolving Credit Facility

Revolving Credit Facility

Letter of Credit

Uncommitted Incremental Loan Facility

Revolving Credit Facility

New Credit Agreement

New Credit Agreement

New Credit Agreement

Revolving Credit Facility

New Credit Agreement

New Credit Agreement

Revolving Credit Facility

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

Maximum

Minimum

Term Loan Facility

Revolving Credit Facility

New Credit Agreement

New Credit Agreement

New Credit Agreement

Maximum

Minimum

Term Loan Facility

Term Loan Facility

Committed Incremental Term Loan

Term Loan Facility

Committed Incremental Term Loan

Term Loan Facility

Committed Incremental Term Loan

Revolving Credit Facility

New Credit Agreement

New Credit Agreement

Term Loan Facility

Committed Incremental Term Loan

New Credit Agreement

New Credit Agreement

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term loan facility borrowing capacity

'

'

'

'

'

'

$340,000,000

$340,000,000

'

'

$70,000,000

$70,000,000

$70,000,000

$80,000,000

'

'

$50,000,000

'

$20,000,000

$100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt, leverage ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.005

4.9

3.25

'

'

0.00375

'

'

'

'

'

'

'

0.0325

0.03

'

'

'

'

'

0.0225

0.02

Debt floor interest rate (percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

'

1.00%

1.00%

'

'

4.25%

5.25%

'

'

'

'

'

Debt term (years)

'

'

'

'

'

'

'

'6 years

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Components of long-term debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt, gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt, including current portion

507,996,000

'

507,996,000

'

529,674,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt

494,704,000

'

494,704,000

'

514,608,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate on debt (percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayments of long-term debt

'

'

2,450,000

340,435,000

'

'

80,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on extinguishment of debt

0

-17,069,000

0

-17,069,000

-17,069,000

'

'

'

'

'

'

'

'

'

'

-1,522,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gains (Losses) on Extinguishment of Debt, Related Call Premium Expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Basis spread on variable rate (percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

3.25%

3.25%

'

'

'

'

'

0.50%

2.25%

2.25%

'

'

Debt description of variable rate basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'one-month LIBOR

'

'

'

'

'

'

'

'

'

'

'

'

Debt, quarterly payments at debt capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

1,050,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ownership percentage of subsidiaries

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Covenant ratio of consolidated total debt to Consolidated Adjusted EBITDA, current year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.95

'

'

'

'

4.3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount repurchased

'

'

'

'

'

'

'

'

8,772,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized deferred cost expensed

'

'

'

'

'

'

'

'

160,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accretion of discount on long-term debt

'

'

222,000

754,000

'

'

'

'

251,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual cash interest savings expected

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of principal amount funded

'

'

'

'

'

'

'

'

'

'

99.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revolving credit facility

'

'

'

'

'

'

'

'

'

485,275,000

'

70,000,000

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Actual ratio of consolidated total debt to Consolidated Adjusted EBITDA

'

'

'

'

'

'

'

'

'

3.55

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Periodic Payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,225,000

'

'

'

$1,050,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, period quarterly amortization payments required

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years 9 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivatives_Income_Statement_I

Derivatives (Income Statement Impact) (Details) (Interest rate contracts, USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Designated Derivative Instruments | Derivatives in Cash Flow Hedging Relationships	'	'	'	'
Effect of Derivative Instruments on Statement of Operations	'	'	'	'
Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)	($375)	$63	($478)	$30
Designated Derivative Instruments | Derivatives in Cash Flow Hedging Relationships | Interest expense and other, net	'	'	'	'
Effect of Derivative Instruments on Statement of Operations	'	'	'	'
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	8	-221	-126	-411
Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion)	0	0	-2	0
Non-Designated Derivative Instruments | Interest expense and other, net	'	'	'	'
Effect of Derivative Instruments on Statement of Operations	'	'	'	'
Amount of Gain (Loss) Recognized in Income on Derivatives	($1)	'	($2)	'

Derivatives_Textual_Details

Derivatives (Textual) (Details) (USD $)

6 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2011

Dec. 31, 2013

Mar. 31, 2010

Mar. 31, 2010

Jun. 30, 2011

Jun. 30, 2014

Jun. 30, 2011

Jun. 30, 2011

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2013

Interest Rate Cash Flow Hedges

Interest Rate Cash Flow Hedges

Interest Rate Cash Flow Hedges

Interest rate cap

Interest rate cap

Interest rate cap

USR Swap one

USR Swap one

USR Swap one

USR Swap two

Interest Rate Swap, Maturing December 2017

Interest Rate Swap, Maturing December 2017

Interest Rate Swap, Maturing December 2017

Interest Rate Swap, Maturing December 2017

Interest Rate Swap, Matures April 2018

Interest Rate Swap, Matures April 2018

Interest Rate Swap, Matures April 2018

agreement

Interest Rate Cash Flow Hedges

Interest Rate Cash Flow Hedges

Interest Rate Cash Flow Hedges

Interest Rate Cash Flow Hedges

Interest Rate Cash Flow Hedges

Interest Rate Cash Flow Hedges

LIBOR

LIBOR

LIBOR

agreement

LIBOR

LIBOR

Derivative [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Variable bank rate debt

$258,500,000

$162,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Variable rate debt as a percent of total debt (percent)

50.90%

29.90%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected reclassification from accumulated other comprehensive loss to interest expense and other, net

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of agreements

'

'

2

'

3

'

'

'

'

'

'

'

'

'

'

'

'

Derivative variable rate basis

'

'

'

'

'

'LIBOR

'

'

'one-month LIBOR

'

'

'

'one-month LIBOR

'

'

'

'one-month LIBOR

Maturity

'

'

'

'

1-Feb-14

'

1-Oct-15

'

'

1-Apr-14

'

'

'

'

'

'

'

Derivative, notional amount

'

'

'

250,000,000

150,000,000

'

'

1,394,000

'

'

3,736,000

'

'

'

3,370,000

'

'

Paid for cap purchase amortized as interest expense

'

'

'

$815,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Fixed rate of interest paid by the Company (percent)

'

'

'

'

'

'

5.71%

'

'

'

'

3.75%

'

'

'

2.87%

'

Recorded interest expense rate (percent)

'

'

'

'

'

'

8.71%

'

'

'

'

3.75%

'

'

'

2.87%

'

Underlying debt interest rate (percent)

'

'

'

'

'

'

3.00%

'

'

'

'

'

'

'

'

'

'

Interest rate agreement, basis spread on variable rate (percent)

'

'

'

2.50%

'

'

'

'

'

'

'

2.50%

'

2.50%

'

2.00%

2.00%

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Income tax (benefit) expense	$1,802	($7,195)	$3,309	($7,333)
Income tax benefit (percentage)	39.30%	-35.70%	41.20%	-32.30%
Unrecognized tax benefits related to various federal and state income tax matters	304	'	304	'
Tax-effected amount that would reduce the company's effective income tax rate if recognized	262	'	262	'
Accrued interest and penalties related to unrecognized tax benefits	$19	'	$19	'

Earnings_Loss_Per_Common_Share2

Earnings (Loss) Per Common Share (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Numerator [Abstract]	'	'	'	'
Net (loss) income attributable to Alliance HealthCare Services, Inc.	$2,784	($12,964)	$4,715	($15,382)
Denominator [Abstract]	'	'	'	'
Weighted-average shares-basic (shares)	10,671	10,629	10,669	10,629
Effect of dilutive securities:	'	'	'	'
Employee stock options (shares)	183	0	203	0
Weighted-average shares-diluted (shares)	10,854	10,629	10,872	10,629
Earnings Per Share, Basic and Diluted [Abstract]	'	'	'	'
Basic (dollars per share)	$0.26	($1.22)	$0.44	($1.45)
Diluted (dollars per share)	$0.26	($1.22)	$0.43	($1.45)
Antidilutive Securities Excluded From Computation Of Diluted Earnings Per Share [Abstract]	'	'	'	'
Weighted-average shares for which exercise price exceeds average market price of common stock (shares)	132	291	134	310
Average exercise price per share that exceeds average market price of common stock (dollars per share)	$44.22	$35.31	$44.25	$34.55

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	Jun. 30, 2014	Mar. 27, 2013
		Superior MRI Services, Inc.
Commitments and Contingencies [Line Items]	'	'
Liability related to guarantees and indemnities	$0	'
Damages sought, minimum	'	$1,000,000

RelatedParty_Transactions_Deta

Related-Party Transactions (Details) (USD $)

3 Months Ended

6 Months Ended

0 Months Ended

0 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Apr. 16, 2007

Jun. 03, 2013

Jun. 30, 2014

Jul. 03, 2013

Jun. 03, 2013

Dec. 02, 2013

Nov. 07, 2013

Oct. 11, 2013

Jun. 03, 2013

Jul. 03, 2013

Nov. 07, 2013

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

New Credit Agreement

Oaktree [Member]

Oaktree [Member]

Oaktree [Member]

Term Loan Facility

Term Loan Facility

Term Loan Facility

Delayed Draw

Committed Incremental Term Loan

Committed Incremental Term Loan

Committed Incremental Term Loan

New Credit Agreement

New Credit Agreement

New Credit Agreement

Term Loan Facility

Delayed Draw

Committed Incremental Term Loan

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares purchased by Oaktree and MTS (shares)

'

'

'

'

4,900,301

'

'

'

'

'

'

'

'

'

'

Percentage of outstanding stock owned by Oaktree and MTS (percent)

50.90%

'

50.90%

'

49.70%

'

'

'

'

'

'

'

'

'

'

Revenues from management agreements with unconsolidated equity investees

$2,241,000

$2,276,000

$4,562,000

$4,520,000

'

'

'

'

'

'

'

'

'

'

'

Amounts of the revenues and expenses

1,783,000

1,814,000

3,687,000

3,623,000

'

'

'

'

'

'

'

'

'

'

'

Debt amount funded

'

'

'

'

'

'

485,275,000

'

'

70,000,000

'

'

40,476,000

9,524,000

'

Term loan facility borrowing capacity

'

'

'

'

'

$340,000,000

'

$340,000,000

$80,000,000

$70,000,000

$70,000,000

$70,000,000

$340,000,000

$80,000,000

$10,000,000

Debt term (years)

'

'

'

'

'

'6 years

'

'

'

'

'

'

'6 years

'

'

Investments_in_Unconsolidated_2

Investments in Unconsolidated Investees (Balance Sheet Data) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Alliance-HNI, LLC and Subsidiaries	'	'
Schedule of financial data of unconsolidated investees, Balance Sheet Data	'	'
Current assets	$4,483	$4,650
Noncurrent assets	11,206	9,732
Current liabilities	2,687	2,810
Noncurrent liabilities	3,950	2,757
Unconsolidated Investees, Including Alliance-HNI, LLC and Subsidiaries and Austin Cyberknife	'	'
Schedule of financial data of unconsolidated investees, Balance Sheet Data	'	'
Current assets	6,823	7,188
Noncurrent assets	12,326	11,058
Current liabilities	3,548	3,569
Noncurrent liabilities	$4,328	$3,382

Investments_in_Unconsolidated_3

Investments in Unconsolidated Investees (Combined Operating Results) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Schedule of financial data of unconsolidated investees, Combined Operating Results	'	'	'	'
Earnings from unconsolidated investee	$1,242	$1,408	$2,240	$3,142
Alliance-HNI, LLC and Subsidiaries	'	'	'	'
Schedule of financial data of unconsolidated investees, Combined Operating Results	'	'	'	'
Revenues	4,225	4,583	8,331	9,081
Expenses	2,266	2,341	4,821	4,318
Net income	1,959	2,242	3,510	4,763
Earnings from unconsolidated investee	979	1,106	1,755	2,382
Unconsolidated Investees, Including Alliance-HNI, LLC and Subsidiaries and Austin Cyberknife	'	'	'	'
Schedule of financial data of unconsolidated investees, Combined Operating Results	'	'	'	'
Revenues	6,765	7,272	13,196	14,009
Expenses	3,210	3,315	6,745	6,906
Net income	3,555	3,957	6,451	7,103
Earnings from unconsolidated investee	$1,242	$1,409	$2,240	$2,951

Investments_in_Unconsolidated_4

Investments in Unconsolidated Investees (Textual) (Details)	Jun. 30, 2014
	investee
Schedule Of Equity Method Investments [Line Items]	'
Number of unconsolidated entities with direct ownership (investee)	3
Minimum	'
Schedule Of Equity Method Investments [Line Items]	'
Percentage of ownership from investees (percent)	15.00%
Maximum	'
Schedule Of Equity Method Investments [Line Items]	'
Percentage of ownership from investees (percent)	50.00%

Stockholders_Deficit_Details

Stockholders' Deficit (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Increase (Decrease) in Stockholders' Deficit [Roll Forward]	'	'	'	'
Beginning balance	'	'	($136,617)	'
Exercise of stock options (shares)	'	'	67,657	3,665
Exercise of stock options	'	'	706	'
Forfeit of restricted stock	'	'	0	'
Issuance of restricted stock	'	'	-140	'
Share-based payment	'	'	710	'
Unrealized gain on hedging transaction, net of tax	'	'	-215	'
Net contributions (distributions)	'	'	-7,264	'
Net (loss) income	6,820	-9,455	11,800	-9,043
Ending balance	-131,020	'	-131,020	'
Common Stock	'	'	'	'
Increase (Decrease) in Stockholders' Deficit [Roll Forward]	'	'	'	'
Beginning balance	'	'	524	'
Beginning balance (shares)	'	'	10,667,136	'
Exercise of stock options (shares)	'	'	67,657	'
Forfeit of restricted stock (shares)	'	'	26,272	'
Forfeit of restricted stock	'	'	0	'
Issuance of restricted stock (shares)	'	'	0	'
Ending balance	525	'	525	'
Ending balance (shares)	10,708,521	'	10,708,521	'
Treasury Stock	'	'	'	'
Increase (Decrease) in Stockholders' Deficit [Roll Forward]	'	'	'	'
Beginning balance	'	'	-2,998	'
Beginning balance (shares)	'	'	-144,921	'
Issuance of restricted stock	'	'	-140	'
Issuance of restricted stock (shares)	'	'	-5,323	'
Ending balance	-3,138	'	-3,138	'
Ending balance (shares)	-150,244	'	-150,244	'
Additional Paid-In Capital	'	'	'	'
Increase (Decrease) in Stockholders' Deficit [Roll Forward]	'	'	'	'
Beginning balance	'	'	23,521	'
Exercise of stock options	'	'	705	'
Share-based payment	'	'	710	'
Net contributions (distributions)	'	'	1,652	'
Ending balance	26,588	'	26,588	'
Accumulated Comprehensive Income (Loss)	'	'	'	'
Increase (Decrease) in Stockholders' Deficit [Roll Forward]	'	'	'	'
Beginning balance	'	'	-82	'
Unrealized gain on hedging transaction, net of tax	'	'	-215	'
Ending balance	-297	'	-297	'
Accumulated Deficit	'	'	'	'
Increase (Decrease) in Stockholders' Deficit [Roll Forward]	'	'	'	'
Beginning balance	'	'	-204,709	'
Net (loss) income	'	'	4,715	'
Ending balance	-199,994	'	-199,994	'
Alliance HealthCare Services, Inc.	'	'	'	'
Increase (Decrease) in Stockholders' Deficit [Roll Forward]	'	'	'	'
Beginning balance	'	'	-183,744	'
Exercise of stock options	'	'	706	'
Forfeit of restricted stock	'	'	0	'
Issuance of restricted stock	'	'	-140	'
Share-based payment	'	'	710	'
Unrealized gain on hedging transaction, net of tax	'	'	-215	'
Net contributions (distributions)	'	'	1,652	'
Net (loss) income	'	'	4,715	'
Ending balance	-176,316	'	-176,316	'
Noncontrolling Interest	'	'	'	'
Increase (Decrease) in Stockholders' Deficit [Roll Forward]	'	'	'	'
Beginning balance	'	'	47,127	'
Net contributions (distributions)	'	'	-8,916	'
Net (loss) income	'	'	7,085	'
Ending balance	$45,296	'	$45,296	'

Segment_Information_Revenue_by

Segment Information (Revenue by Segment) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Summary of revenue by segment	'	'	'	'
Revenue	$111,238	$114,418	$216,603	$224,800
Imaging	'	'	'	'
Summary of revenue by segment	'	'	'	'
Revenue	87,297	94,613	171,935	186,586
Radiation Oncology	'	'	'	'
Summary of revenue by segment	'	'	'	'
Revenue	$23,941	$19,805	$44,668	$38,214

Segment_Information_Components

Segment Information (Components of Revenue) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Summary of components of revenue	'	'	'	'
Revenue	$111,238	$114,418	$216,603	$224,800
MRI	'	'	'	'
Summary of components of revenue	'	'	'	'
Revenue	45,637	47,359	89,822	93,440
PET/CT	'	'	'	'
Summary of components of revenue	'	'	'	'
Revenue	34,178	37,656	67,547	74,406
Radiation Oncology	'	'	'	'
Summary of components of revenue	'	'	'	'
Revenue	23,941	19,805	44,668	38,214
Other Modalities And Other Revenue	'	'	'	'
Summary of components of revenue	'	'	'	'
Revenue	$7,482	$9,598	$14,566	$18,740

Segment_Information_Summary_of

Segment Information (Summary of Segment Income) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Summary of segment income	'	'	'	'
Segment income	$36,669	$38,585	$69,621	$73,746
Imaging	'	'	'	'
Summary of segment income	'	'	'	'
Segment income	33,248	38,311	64,257	73,474
Radiation Oncology	'	'	'	'
Summary of segment income	'	'	'	'
Segment income	11,167	9,121	20,490	16,806
Corporate / Other	'	'	'	'
Summary of segment income	'	'	'	'
Segment income	($7,746)	($8,847)	($15,126)	($16,534)

Segment_Information_Reconcilia

Segment Information (Reconciliation of Net Loss to Segment Income) (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Reconciliation of Net loss to total segment income	'	'	'	'	'
Net (loss) income attributable to Alliance HealthCare Services, Inc.	$2,784	($12,964)	$4,715	($15,382)	'
Income tax (benefit) expense	1,802	-7,195	3,309	-7,333	'
Interest expense and other, net	6,124	11,053	12,362	23,325	'
Amortization expense	1,957	2,911	3,909	6,705	'
Depreciation expense	14,274	16,322	30,069	32,838	'
Share-based payment (included in selling, general and administrative expenses)	376	329	710	735	'
Severance and related costs	1,727	298	1,860	646	'
Noncontrolling interest in subsidiaries	4,036	3,509	7,085	6,339	'
Restructuring charges (Note 2)	1,563	1,890	2,455	3,363	'
Transaction costs	937	0	939	80	'
Impairment charges	236	4,867	236	4,867	'
Loss on extinguishment of debt	0	17,069	0	17,069	17,069
Other non-recurring charges (included in selling, general and administrative expenses	822	633	1,621	950	'
Other non-cash charges (included in other income and expense, net)	31	161	351	190	'
Total segment income	$36,669	$38,585	$69,621	$73,746	'

Segment_Information_Summary_of1

Segment Information (Summary of Net (Loss) Income by Segment) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Summary of net income (loss) by segment	'	'	'	'
Net (loss) income	$2,784	($12,964)	$4,715	($15,382)
Imaging	'	'	'	'
Summary of net income (loss) by segment	'	'	'	'
Net (loss) income	20,623	18,093	37,817	37,746
Radiation Oncology	'	'	'	'
Summary of net income (loss) by segment	'	'	'	'
Net (loss) income	4,642	2,782	8,068	4,031
Corporate / Other	'	'	'	'
Summary of net income (loss) by segment	'	'	'	'
Net (loss) income	($22,481)	($33,839)	($41,170)	($57,159)

Summary_of_Identifiable_Assets

(Summary of Identifiable Assets) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Summary of Company's identifiable assets by segment	'	'
Identifiable assets	$468,085	$489,847
Imaging	'	'
Summary of Company's identifiable assets by segment	'	'
Identifiable assets	210,675	240,317
Radiation Oncology	'	'
Summary of Company's identifiable assets by segment	'	'
Identifiable assets	156,067	158,216
Corporate / Other	'	'
Summary of Company's identifiable assets by segment	'	'
Identifiable assets	$101,343	$91,314

Segment_Information_Summary_of2

Segment Information (Summary of Goodwill by Segment) (Details) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Summary of goodwill by segment	'	'
Beginning balance	$56,975	$56,493
Goodwill acquired during the period	0	0
Impairment charges	0	0
Adjustments to goodwill during the period	0	482
Ending balance	56,975	56,975
Gross goodwill	231,219	'
Accumulated impairment charges	-174,244	'
Imaging	'	'
Summary of goodwill by segment	'	'
Beginning balance	42,166	41,684
Goodwill acquired during the period	0	0
Impairment charges	0	0
Adjustments to goodwill during the period	0	482
Ending balance	42,166	42,166
Gross goodwill	196,508	'
Accumulated impairment charges	-154,342	'
Radiation Oncology	'	'
Summary of goodwill by segment	'	'
Beginning balance	14,809	14,809
Goodwill acquired during the period	0	0
Impairment charges	0	0
Adjustments to goodwill during the period	0	0
Ending balance	14,809	14,809
Gross goodwill	34,711	'
Accumulated impairment charges	-19,902	'
Corporate / Other	'	'
Summary of goodwill by segment	'	'
Beginning balance	0	0
Goodwill acquired during the period	0	0
Impairment charges	0	0
Adjustments to goodwill during the period	0	0
Ending balance	0	0
Gross goodwill	0	'
Accumulated impairment charges	$0	'

Segment_Information_Textual_De

Segment Information (Textual) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Number of operating segments (segment)	'	'	2	'
Number of reportable segments (segment)	'	'	2	'
Imaging	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Payments to Acquire Productive Assets	$4,761	$3,468	$6,828	$5,481
Radiation Oncology	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Payments to Acquire Productive Assets	19	258	19	671
Corporate / Other	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Payments to Acquire Productive Assets	$2,741	$1,075	$6,409	$4,205